Review Article

Current Concepts

The Serotonin Syndrome

Edward W. Boyer, M.D., Ph.D., and Michael Shannon, M.D., M.P.H.

N Engl J Med 2005; 352:1112-1120March 17, 2005DOI: 10.1056/NEJMra041867

Article

The serotonin syndrome is a potentially life-threatening adverse drug reaction that results from therapeutic drug use, intentional self-poisoning, or inadvertent interactions between drugs. Three features of the serotonin syndrome are critical to an understanding of the disorder. First, the serotonin syndrome is not an idiopathic drug reaction; it is a predictable consequence of excess serotonergic agonism of central nervous system (CNS) receptors and peripheral serotonergic receptors.1,2 Second, excess serotonin produces a spectrum of clinical findings.3 Third, clinical manifestations of the serotonin syndrome range from barely perceptible to lethal. The death of an 18-year-old patient named Libby Zion in New York City more than 20 years ago, which resulted from coadminstration of meperidine and phenelzine, remains the most widely recognized and dramatic example of this preventable condition.4

Definition and Epidemiology

The serotonin syndrome is often described as a clinical triad of mental-status changes, autonomic hyperactivity, and neuromuscular abnormalities, but not all of these findings are consistently present in all patients with the disorder (Figure 1Figure 1Spectrum of Clinical Findings.).5,6 Signs of excess serotonin range from tremor and diarrhea in mild cases to delirium, neuromuscular rigidity, and hyperthermia in life-threatening cases. The difficulty for clinicians is that mild symptoms may be easily overlooked, and an inadvertent increase in the dose of the causative agent or the addition of a drug with proserotonergic effects may provoke a dramatic clinical deterioration.

The incidence of the serotonin syndrome is thought to mirror the increasing number of proserotonergic agents being used in clinical practice.7 In 2002, the Toxic Exposure Surveillance System, which receives case descriptions from office-based practices, inpatient settings, and emergency departments, reported 26,733 incidences of exposure to selective serotonin-reuptake inhibitors (SSRIs) that caused significant toxic effects in 7349 persons and resulted in 93 deaths.8,9 The assessment of the serotonin syndrome in therapeutic drug dosing has relied on post-marketing surveillance studies, one of which identified an incidence of 0.4 case per 1000 patient-months for patients who were taking nefazodone.10 Performing a rigorous epidemiologic assessment of the serotonin syndrome, however, is difficult, since more than 85 percent of physicians are unaware of the serotonin syndrome as a clinical diagnosis.10 The syndrome occurs in approximately 14 to 16 percent of persons who overdose on SSRIs.8

Although the serotonin syndrome has occurred in a broad range of clinical environments, several barriers limit the ability of clinicians to diagnose the condition. First, the syndrome may be missed because of its protean manifestations. Clinicians and patients may dismiss symptoms such as tremor with diarrhea or hypertension as inconsequential or unrelated to drug therapy; anxiety and akathisia may be misattributed to the patient's mental state.5,10 Second, a strict application of the diagnostic criteria proposed by Sternbach potentially rules out what are now recognized as mild, early, or subacute cases of the disorder.1,11 Third, clinicians cannot diagnose a condition of which they are unaware, even though the serotonin syndrome is not rare and has been identified in patients of all ages, including the elderly, children, and newborn infants.10,12-14

A striking number of drugs and drug combinations have been associated with the serotonin syndrome (Table 1Table 1Drugs and Drug Interactions Associated with the Serotonin Syndrome.). These include monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, SSRIs, opiate analgesics, over-the-counter cough medicines, antibiotics, weight-reduction agents, antiemetics, antimigraine agents, drugs of abuse, and herbal products; the withdrawal of medications has also been associated with the syndrome.1,4,12,15-23 A single therapeutic dose of an SSRI has caused the serotonin syndrome.12 Moreover, the addition of drugs that inhibit cytochrome isoforms CYP2D6 and CYP3A4 to therapeutic SSRI regimens has been associated with the condition.16,24,25 Administration of serotonergic agents within five weeks after the discontinuation of fluoxetine therapy has produced a drug interaction culminating in the serotonin syndrome, presumably the result of the demethylation of fluoxetine to norfluoxetine, a serotonergic metabolite with a longer serum half-life than its parent compound.13 Specific drugs, such as MAOIs that are irreversible or nonselective or that inhibit monoamine oxidase subtype A, are strongly associated with severe cases of the syndrome, especially when these agents are used in combination with meperidine, dextromethorphan, SSRIs, or methylenedioxymethamphetamine (MDMA, or “ecstasy”).4,8,15,26,27

Manifestations

The serotonin syndrome encompasses a range of clinical findings. Patients with mild cases may be afebrile but have tachycardia, with a physical examination that is notable for autonomic findings such as shivering, diaphoresis, or mydriasis (Figure 2Figure 2Findings in a Patient with Moderately Severe Serotonin Syndrome.). The neurologic examination may reveal intermittent tremor or myoclonus, as well as hyperreflexia.

A representative example of a moderate case of the serotonin syndrome involves such vital-sign abnormalities as tachycardia, hypertension, and hyperthermia. A core temperature as high as 40°C is common in moderate intoxication. Common features of the physical examination are mydriasis, hyperactive bowel sounds, diaphoresis, and normal skin color. Interestingly, the hyperreflexia and clonus seen in moderate cases may be considerably greater in the lower extremities than in the upper extremities; patellar deep-tendon reflexes often demonstrate clonus for several seconds after a single tap of the tendon, whereas the brachioradialis reflex is only slightly increased. Patients may exhibit horizontal ocular clonus. Changes in mental status include mild agitation or hypervigilance, as well as slightly pressured speech. Patients may easily startle or adopt a peculiar head-turning behavior characterized by repetitive rotation of the head with the neck held in moderate extension.

In contrast, a patient with a severe case of the serotonin syndrome may have severe hypertension and tachycardia that may abruptly deteriorate into frank shock. Such patients may have agitated delirium as well as muscular rigidity and hypertonicity. Again, the increase in muscle tone is considerably greater in the lower extremities. The muscle hyperactivity may produce a core temperature of more than 41.1°C in life-threatening cases. Laboratory abnormalities that occur in severe cases include metabolic acidosis, rhabdomyolysis, elevated levels of serum aminotransferase and creatinine, seizures, renal failure, and disseminated intravascular coagulopathy. Many of these abnormalities arise, however, as a consequence of poorly treated hyperthermia.

To better delineate the signs and symptoms that define the serotonin syndrome, the clinical findings in 2222 consecutive cases of self-poisoning with serotonergic drugs were rigorously assessed on the basis of information from a detailed toxicology registry.2 These findings were then compared with the “gold standard,” the assignment of a diagnosis of the serotonin syndrome by a medical toxicologist.2 The clinical findings that had a statistically significant association with the diagnosis of the syndrome were primarily neuromuscular, including hyperreflexia, inducible clonus, myoclonus, ocular clonus, spontaneous clonus, peripheral hypertonicity, and shivering.2 Autonomic derangements were tachycardia on admission, mydriasis, diaphoresis, and the presence of bowel sounds and diarrhea.2 Abnormalities in mental status that were significantly associated with the serotonin syndrome were agitation and delirium.2 Hyperthermia that was caused by muscular hypertonicity, defined in this study as a temperature of more than 38°C, was not as strongly associated with the diagnosis of the serotonin syndrome but occurred in severely intoxicated patients.2

The onset of symptoms is usually rapid, with clinical findings often occurring within minutes after a change in medication or self-poisoning.28 Approximately 60 percent of patients with the serotonin syndrome present within six hours after initial use of medication, an overdose, or a change in dosing.28 Patients with mild manifestations may present with subacute or chronic symptoms, whereas severe cases may progress rapidly to death. The serotonin syndrome is not believed to resolve spontaneously as long as precipitating agents continue to be administered.

Pathophysiology and Molecular Mechanisms

Serotonin is produced by the decarboxylation and hydroxylation of L-tryptophan. Its quantity and actions are tightly regulated by a combination of reuptake mechanisms, feedback loops, and metabolizing enzymes (Figure 3Figure 3Serotonin Biosynthesis and Metabolism.). Serotonin receptors are divided into seven 5-hydroxytryptamine (5-HT) families (5-HT₁ to 5-HT₇), several of which have multiple members (e.g., 5-HT_1A, 5-HT_1B, 5-HT_1C, 5-HT_1D, 5-HT_1E, and 5-HT_1F). Further structural and operational diversity is achieved by allelic polymorphisms, splice variants, receptor isoforms, and the formation of receptor heterodimers.29

Serotonergic neurons in the CNS are found primarily in the midline raphe nuclei, located in the brain stem from the midbrain to the medulla.30 The rostral end of this system assists in the regulation of wakefulness, affective behavior, food intake, thermoregulation, migraine, emesis, and sexual behavior.30 The neurons of the raphe in the lower pons and medulla participate in the regulation of nociception and motor tone.30 In the periphery, the serotonin system assists in the regulation of vascular tone and gastrointestinal motility.30

No single receptor appears to be responsible for the development of the serotonin syndrome, although several lines of evidence converge to suggest that agonism of 5-HT_2A receptors contributes substantially to the condition.31-35 Additional subtypes of serotonin receptors, such as 5-HT_1A, may contribute through a pharmacodynamic interaction in which increased synaptic concentrations of serotonin agonist saturate all receptor subtypes. Noradrenergic CNS hyperactivity may play a critical role, since the degree to which CNS norepinephrine concentrations are increased in the serotonin syndrome may correlate with the clinical outcome.33,35,36 Other neurotransmitters, including N-methyl-D-aspartate (NMDA) receptor antagonists and γ-aminobutyric acid (GABA), may affect the development of the syndrome, but the role of these agents is less clear.33,37 Dopaminergic receptors have been implicated, but this association may arise from pharmacodynamic interactions, direct interactions between serotonin and dopamine receptors, other mechanisms, or a misdiagnosis of the serotonin syndrome as the neuroleptic malignant syndrome.26,33,38,39

Diagnosis

No laboratory tests confirm the diagnosis of the serotonin syndrome. Instead, the presence of tremor, clonus, or akathisia without additional extrapyramidal signs should lead clinicians to consider the diagnosis, which must be inferred from the patient's history and physical examination. When obtaining the patient's history, clinicians should inquire about the use of prescription and over-the-counter drugs, illicit substances, and dietary supplements, since all of these agents have been implicated in the development of the serotonin syndrome. The evolution of symptoms and their rate of change should also be reviewed. Physical examination should include a focused assessment of deep-tendon reflexes, clonus, and muscle rigidity, in addition to an evaluation of the size and reactivity of the pupils, the dryness of the oral mucosa, the intensity of bowel sounds, skin color, and the presence or absence of diaphoresis.

Although several diagnostic criteria have been developed, we prefer the decision rules described in Figure 4Figure 4Algorithm for Diagnosis..2,11,14,40 These rules, when compared with the original diagnostic criteria, are simpler, more sensitive (84 percent vs. 75 percent), and more specific (97 percent vs. 96 percent) for diagnosing the serotonin syndrome.1,2 Clonus (inducible, spontaneous, and ocular) is the most important finding in establishing the diagnosis of the serotonin syndrome.2,27,41 Clinicians should always be aware that hyperthermia and hypertonicity occur in life-threatening cases, but muscle rigidity may mask the highly distinguishing findings of clonus and hyperreflexia and therefore cloud the diagnosis.2,42

The differential diagnosis includes anticholinergic poisoning, malignant hyperthermia, and the neuroleptic malignant syndrome, each of which can be readily distinguished from the serotonin syndrome on clinical grounds and on the basis of the medication history (Table 2Table 2Manifestations of Severe Serotonin Syndrome and Related Clinical Conditions.). Patients with the anticholinergic syndrome have normal reflexes and show the “toxidrome” of mydriasis; agitated delirium; dry oral mucosa; hot, dry, erythematous skin; urinary retention; and an absence of bowel sounds. Hyperactive bowel sounds — along with neuromuscular abnormalities, diaphoresis, and normal skin color — distinguish the serotonin syndrome from the anticholinergic toxidrome.2

Malignant hyperthermia is a pharmacogenetic disorder characterized by increasing concentrations of end-tidal carbon dioxide, hypertonicity, hyperthermia, and metabolic acidosis. The disorder occurs within minutes after exposure to inhalational anesthetic agents.43 On physical examination, the skin is often mottled, with cyanotic areas contrasting with patches of bright red flushing.43 The rigor mortis–like rigidity of skeletal muscles and hyporeflexia that are seen in malignant hyperthermia further distinguish this condition from the serotonin syndrome.43

The neuroleptic malignant syndrome is an idiopathic reaction to dopamine antagonists, a condition that is defined by a slow onset, bradykinesia or akinesia, “lead pipe” muscular rigidity, hyperthermia, fluctuating consciousness, and autonomic instability.44 Signs and symptoms of the neuroleptic malignant syndrome typically evolve during several days, in contrast to the rapid onset and hyperkinesia of the serotonin syndrome. Knowledge of the precipitating drug also helps in distinguishing between syndromes: dopamine antagonists produce bradykinesia, whereas serotonin agonists produce hyperkinesia.45

Management

Management of the serotonin syndrome involves the removal of the precipitating drugs, the provision of supportive care, the control of agitation, the administration of 5-HT_2A antagonists, the control of autonomic instability, and the control of hyperthermia.45 Many cases of the serotonin syndrome typically resolve within 24 hours after the initiation of therapy and the discontinuation of serotonergic drugs, but symptoms may persist in patients taking drugs with long elimination half-lives, active metabolites, or a protracted duration of action. Supportive care, comprising the administration of intravenous fluids and correction of vital signs, remains a mainstay of therapy. However, an abrupt deterioration in the condition of a patient who has been conservatively treated indicates the need for an immediate, aggressive response.1,2,45

The intensity of therapy depends on the severity of illness. Mild cases (e.g., with hyperreflexia and tremor but no fever) can usually be managed with supportive care, removal of the precipitating drugs, and treatment with benzodiazepines. Moderately ill patients should have all cardiorespiratory and thermal abnormalities aggressively corrected and may benefit from the administration of 5-HT_2A antagonists. Hyperthermic patients (those whose temperature is more than 41.1°C) are severely ill and should receive the above therapies as well as immediate sedation, neuromuscular paralysis, and orotracheal intubation.

Control of agitation with benzodiazepines is essential in the management of the serotonin syndrome, regardless of its severity. Benzodiazepines such as diazepam improve survival in animal models and blunt the hyperadrenergic component of the syndrome.37,45 Physical restraints are ill-advised and may contribute to mortality by enforcing isometric muscle contractions that are associated with severe lactic acidosis and hyperthermia.46 If physical restraints are used, they must be rapidly replaced with chemical sedation.

Pharmacologically directed therapy involves the administration of 5-HT_2A antagonists.7,45 Cyproheptadine is the recommended therapy for the serotonin syndrome, although its efficacy has not been rigorously established.7,45 Treatment of the serotonin syndrome in adults may require 12 to 32 mg of the drug during a 24-hour period, a dose that binds 85 to 95 percent of serotonin receptors.47 Clinicians should consider an initial dose of 12 mg of cyproheptadine and then 2 mg every two hours if symptoms continue. Maintenance dosing involves the administration of 8 mg of cyproheptadine every six hours. Cyproheptadine is available only in oral form, but tablets may be crushed and administered by nasogastric tube. Atypical antipsychotic agents with 5-HT_2A–antagonist activity may be beneficial in treating the serotonin syndrome. The sublingual administration of 10 mg of olanzapine has been used successfully, but its efficacy has not been rigorously determined.48 Clinicians desiring a parenteral agent should consider the intramuscular administration of 50 to 100 mg of chlorpromazine.45 Even though chlorpromazine is an outdated therapy that has been replaced in psychiatric practice by newer agents, its use may nonetheless be considered in severe cases.45

Control of autonomic instability involves stabilization of fluctuating pulse and blood pressure. Hypotension arising from MAOI interactions should be treated with low doses of direct-acting sympathomimetic amines (e.g., norepinephrine, phenylephrine, and epinephrine). Direct agonists do not require intracellular metabolism to generate a vasoactive amine, but their concentration in the synapse is regulated by catecholamine-O-methyl transferase. Indirect agents such as dopamine are metabolized to epinephrine and norepinephrine. Under normal conditions, monoamine oxidase limits the intracellular concentration of these metabolites. When inhibited, however, monoamine oxidase cannot control the amount of epinephrine and norepinephrine produced, and an exaggerated hemodynamic response may ensue. Patients in whom hypertension and tachycardia develop, either as a result of pressor therapy or from poisoning itself, should be treated with short-acting agents such as nitroprusside and esmolol.

Control of hyperthermia involves eliminating excessive muscle activity. Although benzodiazepines have a beneficial effect in moderate cases, in severely ill patients with hyperthermia (a temperature of more than 41.1°C) immediate paralysis should be induced with nondepolarizing agents such as vecuronium, followed by orotracheal intubation and ventilation. Clinicians should avoid succinylcholine because of the risk of arrhythmia from hyperkalemia associated with rhabdomyolysis. Recent case reports have shown that premature termination of neuromuscular paralysis was associated with a recrudescence of hyperthermia.49 There is no role for antipyretic agents in the management of the serotonin syndrome; the increase in body temperature is due to muscular activity, not an alteration in the hypothalamic temperature set point.

Potential pitfalls for clinicians include misdiagnosis of the serotonin syndrome, a failure to comprehend its rapidity of progression, and adverse effects of pharmacologically directed therapy. The diagnosis may be clouded by the presence of severe muscle rigidity that obscures myoclonus and hyperreflexia. If the correct diagnosis is not obvious, a prudent course is to withhold antagonist therapy and provide aggressive supportive care, sedation with benzodiazepines, and, if necessary, intubation and paralysis.7 Because of the speed with which the condition of patients declines, physicians should anticipate the need for aggressive therapy before clinical indications are reached.

Therapies such as propranolol, bromocriptine, and dantrolene are not recommended.7,45 Propranolol, a 5-HT_1A antagonist with a long duration of action, may cause hypotension and shock in patients with autonomic instability. Furthermore, propranolol can abolish tachycardia that can be used to determine the duration and effectiveness of therapy.2 Bromocriptine, a dopamine agonist, and dantrolene are not useful therapies; case reports citing their use probably involved a misdiagnosis of another condition as the serotonin syndrome.7,35,45 Bromocriptine has been implicated in the development of the serotonin syndrome, and its use in patients in whom the neuroleptic malignant syndrome is misdiagnosed may worsen serotonergic signs.27,50 According to one report, the administration of bromocriptine and dantrolene to a patient with the serotonin syndrome caused an abrupt increase in temperature, culminating in death.39 This finding is supported by the observation that dantrolene has no effect on survival in animal models.34,35

Antagonist therapy with the use of cyproheptadine and chlorpromazine may have unintended effects. The dosage of cyproheptadine used to treat the serotonin syndrome may cause sedation, but this effect is a goal of therapy and should not deter clinicians from using the drug. Chlorpromazine is an outmoded drug that has been associated with severe orthostatic hypotension and has been thought to aggravate hyperthermia. Patients who require acute parenteral therapy for the serotonin syndrome are often hypertensive and are not ambulatory, so that the risk of orthostatic hypotension is minimized. Hyperthermia in response to neuroleptic administration is an idiopathic response; the normal outcome is hypothermia. Nonetheless, chlorpromazine should not be administered to a patient with hypotension or the neuroleptic malignant syndrome, since the drug could potentially exacerbate clinical findings.

Prevention

The serotonin syndrome can be avoided by a combination of pharmacogenomic research, the education of physicians, modifications in prescribing practices, and the use of technological advances. The application of pharmacogenomic principles can potentially protect patients at risk for the syndrome before the administration of serotonergic agents. Once toxicity occurs, consultation with a medical toxicologist, a clinical pharmacology service, or a poison-control center can identify proserotonergic agents and drug interactions, assist clinicians in anticipating adverse effects, and provide valuable clinical decision-making experience. The avoidance of multidrug regimens is critical to the prevention of the serotonin syndrome. If multiple agents are required, however, computer-based ordering systems and the use of personal digital assistants can detect drug interactions and decrease reliance on memory in drug ordering. Post-marketing surveillance linked to physician education has been proposed to improve awareness of the serotonin syndrome.10

Supported in part by a grant from the National Institute on Drug Abuse (DA-14929, to Dr. Boyer).

This article (10.1056/NEJMra041867) was updated on October 21, 2009, at NEJM.org.

Source Information

From the Division of Medical Toxicology, Department of Emergency Medicine, University of Massachusetts, Worcester (E.W.B.); and the Program in Medical Toxicology, Division of Emergency Medicine, Children's Hospital, Boston (E.W.B., M.S.).

Address reprint requests to Dr. Boyer at IC Smith Bldg., Children's Hospital, 300 Longwood Ave., Boston, MA 02115, or at edward.boyer@tch.harvard.edu.

References

References

1. 1

   Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713
   Web of Science | Medline

2. 2

   Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96:635-642
   CrossRef | Medline

3. 3

   Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960;10:1076-1078
   Web of Science | Medline

4. 4

   Asch DA, Parker RM. The Libby Zion case: one step forward or two steps backward? N Engl J Med 1988;318:771-775
   Full Text | Web of Science | Medline

5. 5

   Sampson E, Warner JP. Serotonin syndrome: potentially fatal but difficult to recognize. Br J Gen Pract 1999;49:867-868
   Web of Science | Medline

6. 6

   Martin T. Serotonin syndrome. Ann Emerg Med 1996;28:520-526
   CrossRef | Web of Science | Medline

7. 7

   Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615-619
   CrossRef | Medline

8. 8

   Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004;42:277-285
   CrossRef | Medline

9. 9

   Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003;21:353-421
   CrossRef | Web of Science | Medline

10. 10

    Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999;49:871-874
    Web of Science | Medline

11. 11

    Hegerl U, Bottlender R, Gallinat J, Kuss HJ, Ackenheil M, Moller HJ. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci 1998;248:96-103
    CrossRef | Web of Science | Medline

12. 12

    Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med 1999;33:457-459
    CrossRef | Web of Science | Medline

13. 13

    Isbister GK, Dawson A, Whyte IM, Prior FH, Clancy C, Smith AJ. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001;85:F147-F148
    CrossRef | Web of Science | Medline

14. 14

    Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003;60:720-726
    CrossRef | Web of Science | Medline

15. 15

    Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002;71:837-844
    CrossRef | Web of Science | Medline

16. 16

    Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 1999;19:894-896
    CrossRef | Web of Science | Medline

17. 17

    Gardner MD, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother 1998;32:33-38
    CrossRef | Web of Science | Medline

18. 18

    Giese SY, Neborsky R. Serotonin syndrome: potential consequences of Meridia combined with demerol or fentanyl. Plast Reconstr Surg 2001;107:293-294
    CrossRef | Web of Science | Medline

19. 19

    DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001;15:1281-1285
    CrossRef | Web of Science | Medline

20. 20

    Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse reactions. J Psychoactive Drugs 1998;30:367-369
    CrossRef | Web of Science | Medline

21. 21

    Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61:2163-2175
    CrossRef | Web of Science | Medline

22. 22

    Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. J Clin Psychopharmacol 2002;22:440-441
    CrossRef | Web of Science | Medline

23. 23

    Turkel SB, Nadala JG, Wincor MZ. Possible serotonin syndrome in association with 5-HT(3) antagonist agents. Psychosomatics 2001;42:258-260
    CrossRef | Web of Science | Medline

24. 24

    Kaneda Y, Kawamura I, Fujii A, Ohmori T. Serotonin syndrome -- `potential' role of the CYP2D6 genetic polymorphism in Asians. Int J Neuropsychopharmacol 2002;5:105-106
    CrossRef | Web of Science | Medline

25. 25

    Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf 1997;17:390-406
    CrossRef | Web of Science | Medline

26. 26

    Demirkiran M, Jankivic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol 1996;19:157-164
    CrossRef | Web of Science | Medline

27. 27

    Gillman PK. Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med J Aust 1997;167:109-111
    Web of Science | Medline

28. 28

    Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome: presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000;79:201-209
    CrossRef | Web of Science | Medline

29. 29

    Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203
    Web of Science | Medline

30. 30

    Saper CB. Brain stem modulation of sensation, movement, and consciousness. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principles of neural science. 4th ed. New York: McGraw-Hill, 2000:896.
    

31. 31

    Van Oekelen D, Megens A, Meert T, Luyten WH, Leysen JE. Functional study of rat 5-HT2A receptors using antisense oligonucleotides. J Neurochem 2003;85:1087-1100
    CrossRef | Web of Science | Medline

32. 32

    Isbister GK. Serotonin syndrome, mydriasis, and cyproheptadine. Ann Pharmacother 2001;35:1672-1673
    CrossRef | Web of Science | Medline

33. 33

    Nisijima K, Shioda K, Yoshino T, Takano K, Kato S. Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. Pharmacopsychiatry 2004;37:57-62
    CrossRef | Web of Science | Medline

34. 34

    Isbister GK, Whyte IM. Serotonin toxicity and malignant hyperthermia: role of 5-HT2 receptors. Br J Anaesth 2002;88:603-604
    CrossRef | Web of Science | Medline

35. 35

    Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT_2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 2001;890:23-31
    CrossRef | Web of Science | Medline

36. 36

    Done CJ, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 1994;33:411-421
    CrossRef | Web of Science | Medline

37. 37

    Nisijima K, Shioda K, Yoshino T, Takano K, Kato S. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int 2003;43:155-164
    CrossRef | Web of Science | Medline

38. 38

    Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry 1996;29:159-161
    Web of Science | Medline

39. 39

    Kline SS, Mauro LS, Scala-Barnett DM, Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 1989;8:510-514
    Medline

40. 40

    Kaneda Y, Ohmori T, Fujii A. The serotonin syndrome: investigation using the Japanese version of the Serotonin Syndrome Scale. Psychiatry Res 2001;105:135-142
    CrossRef | Web of Science | Medline

41. 41

    Baloh RW, Dietz J, Spooner JW. Myoclonus and ocular oscillations induced by L-tryptophan. Ann Neurol 1982;11:95-97
    CrossRef | Web of Science | Medline

42. 42

    Whyte I, Dawson A. Redefining the serotonin syndrome. J Toxicol Clin Toxicol 2002;40:668-669 abstract.
    

43. 43

    Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. Best Pract Res Clin Anaesthesiol 2003;17:519-533
    CrossRef | Medline

44. 44

    Guze BH, Baxter LR Jr. Neuroleptic malignant syndrome. N Engl J Med 1985;313:163-166
    Full Text | Web of Science | Medline

45. 45

    Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999;13:100-109
    CrossRef | Web of Science | Medline

46. 46

    Hick JL, Smith SW, Lynch MT. Metabolic acidosis in restraint-associated cardiac arrest: a case series. Acad Emerg Med 1999;6:239-245
    CrossRef | Web of Science | Medline

47. 47

    Kapur S, Zipursky RB, Jones C, Wilson AA, DaSilva JD, Houle S. Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry 1997;154:884-884
    Web of Science | Medline

48. 48

    Boddy R, Ali R, Dowsett R. Use of sublingual olanzapine in serotonin syndrome. J Toxicol Clin Toxicol 2004;42:725-725 abstract.
    

49. 49

    Olsen D, Dart R, Robinett M. Severe serotonin syndrome from escitalopram overdose. J Toxicol Clin Toxicol 2004;42:744-745 abstract.
    

50. 50

    Snider SR, Hutt C, Stein B, Fahn S. Increase in brain serotonin produced by bromocriptine. Neurosci Lett 1975;1:237-241
    CrossRef | Web of Science

Citing Articles (359)

Citing Articles

1. 1

   Raúl López-Arnau, José Martínez-Clemente, Marcel·li Carbó, David Pubill, Elena Escubedo, Jorge Camarasa. (2013) An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as “bath salts”. Progress in Neuro-Psychopharmacology and Biological Psychiatry 45, 64-72
   

2. 2

   Adam Bosak, Frank LoVecchio, Michael Levine. (2013) Recurrent Seizures and Serotonin Syndrome Following “2C-I” Ingestion. Journal of Medical Toxicology 9:2, 196-198
   

3. 3

   Zhiyuan Ma, Mary Rudacille, Howard M. Prentice, Rui Tao. (2013) Characterization of electroencephalographic and biochemical responses at 5-HT promoting drug-induced onset of serotonin syndrome in rats. Journal of Neurochemistry 125:5, 774-789
   

4. 4

   Adam Michael Stewart, Jonathan Cachat, Siddharth Gaikwad, Kyle S.L. Robinson, Michael Gebhardt, Allan V. Kalueff. (2013) Perspectives on experimental models of serotonin syndrome in zebrafish. Neurochemistry International 62:6, 893-902
   

5. 5

   Bill McCarberg, Penny Tenzer. (2013) Complexities in the pharmacologic management of osteoarthritis pain. Current Medical Research and Opinion 29:5, 539-548
   

6. 6

   Natasha N. Bray, Aaron Heath, Julietta Militello. (2013) Migraine: Burden of disease, treatment, and prevention. Osteopathic Family Physician 5:3, 116-122
   

7. 7

   David H. Jang, Lewis S. Nelson, Robert S. Hoffman. (2013) Methylene Blue for Distributive Shock: A Potential New Use of an Old Antidote. Journal of Medical Toxicology
   

8. 8

   J. Dave Barry, Brandon K. Wills. (2013) Neurotoxic Emergencies. Psychiatric Clinics of North America
   

9. 9

   Rafael Guimarães dos Santos. (2013) A Critical Evaluation of Reports Associating Ayahuasca with Life-Threatening Adverse Reactions. Journal of Psychoactive Drugs 45:2, 179-188
   

10. 10

    Bradley M. Wright, Edward H. Eiland, Raymond Lorenz. (2013) Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence-Based Support from the Medical Literature. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:3, 344-359
    

11. 11

    D. Vodovar, C. Le Beller, A. Lillo-Le-Louet, T. Hanslik, B. Megarbane. (2013) Fièvre médicamenteuse : un diagnostic à ne pas oublier. La Revue de Médecine Interne
    

12. 12

    Allana M. Krolikowski, Alex Koyfman. (2013) Methamphetamine and MDMA: ‘Safe’ drugs of abuse. African Journal of Emergency Medicine
    

13. 13

    Jana Hudcova, Donald E Craven. Ventilator-associated pneumonia. In: Hospital-Acquired Pneumonia. Future Medicine Ltd, 2013:48-65.
    

14. 14

    Giuseppe Ciccotto, Maike Blaya, Roger E. Kelley. (2013) Stiff Person Syndrome. Neurologic Clinics 31:1, 319-328
    

15. 15

    Chi Chiu Wang, Ellen Billett, Astrid Borchert, Hartmut Kuhn, Christoph Ufer. (2013) Monoamine oxidases in development. Cellular and Molecular Life Sciences 70:4, 599-630
    

16. 16

    Elisabeth Falzone, Clément Hoffmann, Hawa Keita. (2013) Postoperative Analgesia in Elderly Patients. Drugs & Aging 30:2, 81-90
    

17. 17

    Jennifer J. Davis, Nathan S. Buck, Jeffrey D. Swenson, Ken B. Johnson, Patrick E. Greis. (2013) Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil. Journal of Clinical Anesthesia 25:1, 52-54
    

18. 18

    Boris Birmaher, Dara Sakolsky. Pharmacological Treatment of Anxiety Disorders in Children and Adolescents. In: The Wiley-Blackwell Handbook of The Treatment of Childhood and Adolescent Anxiety. John Wiley & Sons, Ltd., 2013:229-248.
    

19. 19

    S. In: Ferri's Clinical Advisor 2013. Elsevier, 2013:970-1062.
    

20. 20

    Jennifer M. Hall, James L. Jacobson. Neuroleptic Malignant Syndrome. In: Critical Care Secrets. Elsevier, 2013:565-570.
    

21. 21

    Hojo Sasaki, Kazuhiko Yumoto, Taikan Nanao, Hideo Nishizawa, Syuhei Funada, Hajime Aoki, Kenichi Kato. (2013) Cardiogenic shock due to takotsubo cardiomyopathy associated with serotonin syndrome. Journal of Cardiology Cases 7:1, e1-e3
    

22. 22

    Yoko Miyasaka. (2013) Takotsubo cardiomyopathy associated with serotonin syndrome: A disease that we should be aware of. Journal of Cardiology Cases 7:1, e27-e28
    

23. 23

    Brad E. Cooper, Celeste A. Sejnowski. (2013) Serotonin Syndrome. AACN Advanced Critical Care 24:1, 15-20
    

24. 24

    Daniela J Conrado, Hobart L Rogers, Issam Zineh, Michael A Pacanowski. (2013) Consistency of drug–drug and gene–drug interaction information in US FDA-approved drug labels. Pharmacogenomics 14:2, 215-223
    

25. 25

    Rafael Guimarães dos Santos. (2013) Safety and Side Effects of Ayahuasca in Humans—An Overview Focusing on Developmental Toxicology. Journal of Psychoactive Drugs 45:1, 68-78
    

26. 26

    Lampros Samartzis, Paraskevi Savvari, Sofoklis Kontogiannis, Stavros Dimopoulos. (2013) Linezolid Is Associated with Serotonin Syndrome in a Patient Receiving Amitriptyline, and Fentanyl: A Case Report and Review of the Literature. Case Reports in Psychiatry 2013, 1-5
    

27. 27

    Jaime M. Levine. (2013) Common Drug Interactions Following Traumatic Brain Injury. Journal of Head Trauma Rehabilitation 28:2, 151-154
    

28. 28

    David Myland Kaufman, Mark J. Milstein. Muscle Disorders. In: Kaufman's Clinical Neurology for Psychiatrists. Elsevier, 2013:83-105.
    

29. 29

    Kane O. Pryor, Kingsley P. Storer. Drugs for Neuropsychiatric Disorders. In: Pharmacology and Physiology for Anesthesia. Elsevier, 2013:180-207.
    

30. 30

    David Brady, Jacob Teitelbaum, Alan Weiss. Fibromyalgia. In: Advancing Medicine with Food and Nutrients, Second Edition. CRC Press, 2012:637-656.
    

31. 31

    Sébastien Beaune, Jacques Callebert, Frédéric J. Baud, Patricia Risède, Philippe Juvin, Bruno Mégarbane. (2012) Mechanisms of high-dose citalopram-induced death in a rat model. Toxicology 302:2-3, 248-254
    

32. 32

    Koichi Nisijima, Kyoko Kuboshima, Katsutoshi Shioda, Tatuki Yoshino, Tatsunori Iwamura, Satoshi Kato. (2012) Memantine attenuates 3,4-methylenedioxymethamphetamine-induced hyperthermia in rats. Neuroscience Letters 531:2, 198-203
    

33. 33

    Ilona Csoti, Alexander Storch, Walter Müller, Wolfgang H. Jost. (2012) Drug interactions with selegiline versus rasagiline. Basal Ganglia 2:4, S27-S31
    

34. 34

    Martin Lieb, Rainer Rupprecht, Thomas C. Baghai. (2012) Für jeden Patienten den optimalen Wirkstoff finden. NeuroTransmitter 23:12, 26-38
    

35. 35

    Jill Leslie Littrell, Jeffrey R. Lacasse. (2012) The Controversy Over Antidepressant Drugs in an Era of Evidence-Based Practice. Social Work in Mental Health 10:6, 445-463
    

36. 36

    Tyson L Ware, Kate McCloskey, Monique M Ryan, Noel Cranswick. (2012) VENLAFAXINE INGESTION IN A 4-YEAR-OLD GIRL. Journal of Paediatrics and Child Health 48:11, 1047-1048
    

37. 37

    Kuntheavy I. Lorenzini, Alexandra Calmy, Juan Ambrosioni, Benjamin Assouline, Youssef Daali, Marc Fathi, Michela Rebsamen, Jules Desmeules, Caroline F. Samer. (2012) Serotonin syndrome following drug–drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient. AIDS 26:18, 2417-2418
    

38. 38

    Paul E. Rolan. (2012) Drug Interactions with Triptans. CNS Drugs 26:11, 949-957
    

39. 39

    Philip E Grgurich, Jana Hudcova, Yuxiu Lei, Akmal Sarwar, Donald E Craven. (2012) Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert Review of Respiratory Medicine 6:5, 533-555
    

40. 40

    Paul Howard, Robert Twycross, John Shuster, Mary Mihalyo, Andrew Wilcock. (2012) Antidepressant Drugs. Journal of Pain and Symptom Management 44:5, 763-783
    

41. 41

    Saskia J. Rietjens, Laura Hondebrink, Remco H. S. Westerink, Jan Meulenbelt. (2012) Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions. Critical Reviews in Toxicology1-23
    

42. 42

    Matthew W. Hedge. (2012) Miscellaneous Central Nervous System Intoxicants. Critical Care Clinics 28:4, 587-600
    

43. 43

    Christine J. Choe, Graham J. Emslie, Taryn L. Mayes. (2012) Depression. Child and Adolescent Psychiatric Clinics of North America 21:4, 807-829
    

44. 44

    Liesbeth Decoutere, Sabrina Winter, Liesbeth Weyden, Isabel Spriet, Maarten Schrooten, Jos Tournoy, Katleen Fagard. (2012) A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge. International Journal of Clinical Pharmacy 34:5, 686-688
    

45. 45

    Kate Thomson, Barb Henry. (2012) Oncology Clinical Challenges: Caring for Patients With Preexisting Psychiatric Illness. Clinical Journal of Oncology Nursing 16:5, 471-480
    

46. 46

    Jennifer L. Pilgrim, Dimitri Gerostamoulos, Olaf H. Drummer. (2012) The role of toxicology interpretations in prevention of sudden death. Forensic Science, Medicine, and Pathology 8:3, 263-269
    

47. 47

    Jonathan E. Sevransky, O. Joseph Bienvenu, Karin J. Neufeld, Dale M. Needham. (2012) Treatment of four psychiatric emergencies in the intensive care unit. Critical Care Medicine 40:9, 2662-2670
    

48. 48

    JAMES J. LAMBERG, VITALY N. GORDIN. (2012) Serotonin Syndrome in a Patient with Chronic Pain Polypharmacy. Pain Medicineno-no
    

49. 49

    Kendra J. Grubb, Jamie L.W. Kennedy, James D. Bergin, Danja S. Groves, John A. Kern. (2012) The role of methylene blue in serotonin syndrome following cardiac transplantation: A case report and review of the literature. The Journal of Thoracic and Cardiovascular Surgery
    

50. 50

    J.J. Elizondo Armendáriz, E. Pellejero Hernando, M.M. Noceda Urarte, M. Gutiérrez Valencia. (2012) Probable síndrome serotoninérgico por interacción entre linezolid y meperidina. Farmacia Hospitalaria 36:5, 448-449
    

51. 51

    Saumya S. Jamuar, Stephanie A. Newton, Sanjay P. Prabhu, Leah Hecht, Karen C. Costas, Ann E. Wessel, David J. Harris, Irina Anselm, Gerard T. Berry. (2012) Rhabdomyolysis, acute renal failure, and cardiac arrest secondary to status dystonicus in a child with glutaric aciduria type I. Molecular Genetics and Metabolism 106:4, 488-490
    

52. 52

    Brett A. English, Marcus Dortch, Larry Ereshefsky, Stanford Jhee. (2012) Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting. Current Psychiatry Reports 14:4, 376-390
    

53. 53

    Shruti Kant, Erica Liebelt. (2012) Recognizing Serotonin Toxicity in the Pediatric Emergency Department. Pediatric Emergency Care 28:8, 817-821
    

54. 54

    Zdeněk Fišar. (2012) Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. Progress in Neuro-Psychopharmacology and Biological Psychiatry 38:1, 68-77
    

55. 55

    Christopher Dardis, Eghosa Omoregie, Vanthanh Ly. (2012) Fatal Serotonin Syndrome Precipitated by Oxcarbazepine in a Patient Using an Selective Serotonin Reuptake Inhibitor. The Neurologist 18:4, 204-205
    

56. 56

    Josh Mugele, Kristine A. Nañagas, Laura M. Tormoehlen. (2012) Serotonin Syndrome Associated With MDPV Use: A Case Report. Annals of Emergency Medicine 60:1, 100-102
    

57. 57

    Angelina O. Danquah, Soottawat Benjakul, Benjamin K. Simpson. Biogenic Amines in Foods. In: Food Biochemistry and Food Processing. Wiley-Blackwell, 2012:820-832.
    

58. 58

    Murat Oz, Dmytro Isaev, Dietrich E Lorke, Muhammed Hasan, Georg Petroianu, Toni S Shippenberg. (2012) Methylene blue inhibits function of the 5-HT transporter. British Journal of Pharmacology 166:1, 168-176
    

59. 59

    Maria Rosaria Muscatello, Edoardo Spina, Borwin Bandelow, David S. Baldwin. (2012) Clinically relevant drug interactions in anxiety disorders. Human Psychopharmacology: Clinical and Experimental 27:3, 239-253
    

60. 60

    Lisa Wilson, Thomas Rooney, Reginald F. Baugh, Belinda Millington. (2012) Recognition and management of perioperative serotonin syndrome. American Journal of Otolaryngology 33:3, 319-321
    

61. 61

    Suneeta Gollapudy, Vikram Kumar, M. Saeed Dhamee. (2012) A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. Journal of Clinical Anesthesia 24:3, 251-252
    

62. 62

    Carlos Rojas-Fernandez, Mina Mikhail. (2012) Contemporary concepts in the pharmacotherapy of depression in older people. Canadian Pharmacists Journal 145:3, 128-135.e2
    

63. 63

    Hossein Sanaei-Zadeh. (2012) Diphenhydramine overdose and serotonin syndrome. Psychiatry and Clinical Neurosciences 66:3, 244-245
    

64. 64

    Christopher P Alderman, Anita C Abarno, Dasha Loutchkina, Joanna E Hogan. (2012) Psychotropic drug-related problems in the elderly. Aging Health 8:2, 147-159
    

65. 65

    E. K. Morrison, A. S. Rowe. (2012) Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia. Journal of Clinical Pharmacy and Therapeuticsno-no
    

66. 66

    Ruben Thanacoody. (2012) Serotonin syndrome. Medicine 40:2, 63-64
    

67. 67

    Peter De Paepe, Sabine Lemoyne, Walter Buylaert. (2012) Disorders of Consciousness Induced by Intoxication. Neurologic Clinics 30:1, 359-384
    

68. 68

    Grégory Baptista, Céline Eiden, Paul Monguillot, Christelle Philibert, Claude Jeandel. (2012) Serotonin syndrome during treatment with low dose of escitalopram associated with miconazole mucoadhesive tablet: a suspected drug interaction. International Psychogeriatrics1-3
    

69. 69

    Dara Sakolsky, Boris Birmaher. Selective Serotonin Reuptake Inhibitors (SSRIs). In: Pharmacotherapy of Child and Adolescent Psychiatric Disorders. John Wiley & Sons, Ltd, 2012:131-154.
    

70. 70

    Charlotte M. Heleniak, Tejal Kaur, Kareem D. Ghalib, Moira A. Rynn. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders. In: Pharmacotherapy of Child and Adolescent Psychiatric Disorders. John Wiley & Sons, Ltd, 2012:105-129.
    

71. 71

    Edoardo Spina, Gianluca Trifirò, Filippo Caraci. (2012) Clinically Significant Drug Interactions with Newer Antidepressants. CNS Drugs 26:1, 39-67
    

72. 72

    Michael A. Thomas, Parag P. Joshi, Rebecca D. Klaper. (2012) Gene-class analysis of expression patterns induced by psychoactive pharmaceutical exposure in fathead minnow (Pimephales promelas) indicates induction of neuronal systems. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 155:1, 109-120
    

73. 73

    Kerri A. Schoedel, Laura E. Pope, Edward M. Sellers. (2012) Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers. Clinical Drug Investigation1
    

74. 74

    Kenneth R. Alper, Marina Stajić, James R. Gill. (2012) Fatalities Temporally Associated with the Ingestion of Ibogaine. Journal of Forensic Sciencesno-no
    

75. 75

    Chronic Disease Management. In: The Cat. Elsevier, 2012:1134-1164.
    

76. 76

    Steven McGee. Temperature. In: Evidence-Based Physical Diagnosis. Elsevier, 2012:135-144.
    

77. 77

    Peter Manu. Medical Consultation in Psychiatry. In: Goldman's Cecil Medicine. Elsevier, 2012:2492-2496.
    

78. 78

    Mark Dennis, William Talbot Bowen, Lucy Cho. Neurological Signs. In: Mechanisms of clinical signs. Elsevier, 2012:265-442.
    

79. 79

    Pinky Dharmshaktu, Vandana Tayal, Bhupinder Singh Kalra. (2012) Efficacy of Antidepressants as Analgesics: A Review. The Journal of Clinical Pharmacology 52:1, 6-17
    

80. 80

    Brandon J. Warrick, John Wilson, Matthew Hedge, Scott Freeman, Karen Leonard, Cynthia Aaron. (2011) Lethal Serotonin Syndrome After Methylone and Butylone Ingestion. Journal of Medical Toxicology
    

81. 81

    J. M. Butterfield, K. R. Lawrence, A. Reisman, D. B. Huang, C. A. Thompson, T. P. Lodise. (2011) Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. Journal of Antimicrobial Chemotherapy
    

82. 82

    Miklós Szólics, Muhammad Chaudhry, Milos Ljubisavljevic, Peter Corr, Hashim A. Samir, Klaus Neidl van Gorkom. (2011) Neuroimaging findings in a case of fluoxetine overdose. Journal of Neuroradiology
    

83. 83

    Jennifer L. Pilgrim, Dimitri Gerostamoulos, Olaf H. Drummer. (2011) Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. International Journal of Legal Medicine 125:6, 803-815
    

84. 84

    Linda Berney-Meyer, Tracey Putt, John Schollum, Robert Walker. (2011) Nephrotoxicity of recreational party drugs. Nephrologyno-no
    

85. 85

    J Mestres, S A Seifert, T I Oprea. (2011) Linking Pharmacology to Clinical Reports: Cyclobenzaprine and Its Possible Association With Serotonin Syndrome. Clinical Pharmacology & Therapeutics 90:5, 662-665
    

86. 86

    B. Rozec, R. Cinotti, Y. Blanloeil. (2011) Complications liées à l’utilisation périopératoire des médicaments antidépresseurs. Annales Françaises d'Anesthésie et de Réanimation 30:11, 828-840
    

87. 87

    Susannah Davies, Terry Lee, John Ramsey, Paul I. Dargan, David M. Wood. (2011) Risk of caffeine toxicity associated with the use of ‘legal highs’ (novel psychoactive substances). European Journal of Clinical Pharmacology
    

88. 88

    H.J. Lee, M.K. Park, S.Y. Kim, H.Y. Park Choo, A.Y. Lee, C.H. Lee. (2011) Serotonin induces melanogenesis via serotonin receptor 2A. British Journal of Dermatologyno-no
    

89. 89

    Jack J. Chen. (2011) Pharmacologic Safety Concerns in Parkinson's Disease: Facts and Insights. International Journal of Neuroscience 121:S2, 45-52
    

90. 90

    Elizabeth A Wilson. (2011) Neurological entanglements: The case of paediatric depressions, SSRIs and suicidal ideation. Subjectivity 4:3, 277-297
    

91. 91

    Luzius A. Steiner. (2011) Postoperative delirium. Part 1. European Journal of Anaesthesiology 28:9, 628-636
    

92. 92

    Afaf K. El-Ansary, Abir Ben Bacha, Layla Y. Al- Ayahdi. (2011) Relationship between chronic lead toxicity and plasma neurotransmitters in autistic patients from Saudi Arabia. Clinical Biochemistry 44:13, 1116-1120
    

93. 93

    R. Afshari, R. Afshar, B. Mégarbane. (2011) Tramadol overdose: review of the literature. Réanimation 20:5, 436-441
    

94. 94

    Daniel D. Skaar, Heidi O'Connor. (2011) Potentially serious drug-drug interactions among community-dwelling older adult dental patients. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 112:2, 153-160
    

95. 95

    Teppei Tanaka, Akira Takasu, Aihide Yoshino, Keiko Terazumi, Makoto Ide, Soichiro Nomura, Toshihisa Sakamoto. (2011) Diphenhydramine overdose mimicking serotonin syndrome. Psychiatry and Clinical Neurosciences 65:5, 534-534
    

96. 96

    J. Dave Barry, Brandon K. Wills. (2011) Neurotoxic Emergencies. Neurologic Clinics 29:3, 539-563
    

97. 97

    L. E. Peacock, F. Wright. (2011) Serotonin syndrome secondary to tramadol and citalopram. Age and Ageing 40:4, 528-528
    

98. 98

    V. Parks, A.W. Philipp, S. Raje, A. Plotka, L.E. Schechter, J. Connell, S. Chalon. (2011) Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study. European Neuropsychopharmacology
    

99. 99

    Aleeze S Moss, Daniel A Monti, Jay D Amsterdam, Andrew B Newberg. (2011) Complementary and alternative medicine therapies in mood disorders. Expert Review of Neurotherapeutics 11:7, 1049-1056
    

100. 100

     Zachary P. Kilpatrick, G. Bard Ermentrout. (2011) Hallucinogen persisting perception disorder in neuronal networks with adaptation. Journal of Computational Neuroscience
     

101. 101

     Ken Gillman. (2011) Hyperthermic fatalities of uncertain cause. Neuropathology 31:3, 306-307
     

102. 102

     G. Talarico, G. Tosto, S. Pietracupa, E. Piacentini, M. Canevelli, G. L. Lenzi, G. Bruno. (2011) Serotonin toxicity: a short review of the literature and two case reports involving Citalopram. Neurological Sciences 32:3, 507-509
     

103. 103

     Jon K. Slettedal, Dag Olav V. Nilssen, Morten Magelssen, Else Marit Løberg, Jan Maehlen. (2011) Brain pathology in fatal serotonin syndrome: Presentation of two cases. Neuropathology 31:3, 265-270
     

104. 104

     J. L. Pilgrim, D. Gerostamoulos, Olaf H. Drummer. (2011) Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Forensic Science, Medicine, and Pathology 7:2, 162-184
     

105. 105

     Jon K. Slettedal, Dag Olav V. Nilssen, Morten Magelssen, Else Marit Løberg, Jan Maehlen. (2011) RESPONSE. Neuropathology 31:3, 307-308
     

106. 106

     A. Álvarez Omar, B.J. Anía Lafuente, F. Rodríguez Otero, P. Betancor León. (2011) La hipertensión arterial, ¿factor de riesgo para el síndrome serotoninérgico?. Hipertensión y Riesgo Vascular 28:3, 112-114
     

107. 107

     J.L. Pilgrim, D. Gerostamoulos, N. Woodford, Olaf H. Drummer. (2011) Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Science International
     

108. 108

     Christopher R. Newey, Elias Khawam, Kathy Coffman. (2011) Two Cases of Serotonin Syndrome with Venlafaxine and Calcineurin Inhibitors. Psychosomatics 52:3, 286-290
     

109. 109

     Brian D. Poeschla, Pauline Bartle, Karen P. Hansen. (2011) Serotonin syndrome associated with polypharmacy in the elderly. General Hospital Psychiatry 33:3, 301.e9-301.e11
     

110. 110

     Philip J. Mease, Kelly Dundon, Piercarlo Sarzi-Puttini. (2011) Pharmacotherapy of fibromyalgia. Best Practice & Research Clinical Rheumatology 25:2, 285-297
     

111. 111

     Antje Lewien, Laura Kranaster, Carolin Hoyer, Hasan Elkin, Alexander Sartorius. (2011) Escitalopram-Related Rhabdomyolysis. Journal of Clinical Psychopharmacology 31:2, 251-253
     

112. 112

     Lynette Cusack, Charlotte de Crespigny, Peter Athanasos. (2011) Heatwaves and their impact on people with alcohol, drug and mental health conditions: a discussion paper on clinical practice considerations. Journal of Advanced Nursing 67:4, 915-922
     

113. 113

     Sari Nakagawa, Yoshiaki Okamoto, Satoru Tsuneto, Hitoshi Tanimukai, Sho Goya, Yoichi Matsuda, Yumiko Oono, Mamiko Tsugane, Etsuko Uejima. (2011) Can Milnacipran Used for Neuropathic Pain in Patients with Advanced Cancer Cause Neuromuscular and Somatosensory Disorders?. Journal of Palliative Medicine 14:4, 403-405
     

114. 114

     Zhanna Livshits, Robert S. Hoffman. (2011) Letter to the Editor regarding the published study “Deaths involving serotonergic drugs”. Forensic Science International 207:1-3, e62
     

115. 115

     Kenneth Klemow, Andrew Bartlow, Justin Crawford, Neil Kocher, Jay Shah, Michael Ritsick. Medical Attributes of St. John's Wort (Hypericum perforatum). CRC Press, 2011:211-237.
     

116. 116

     Betty L. Elder, Victoria Mosack. (2011) Genetics of Depression: An Overview of the Current Science. Issues in Mental Health Nursing 32:4, 192-202
     

117. 117

     Leo J. Schep, Robin J. Slaughter, J. Allister Vale, D. Michael G. Beasley, Paul Gee. (2011) The clinical toxicology of the designer “party pills” benzylpiperazine and trifluoromethylphenylpiperazine. Clinical Toxicology 49:3, 131-141
     

118. 118

     Celeste N. Rudisill, Zaina P. Qureshi, John M. Armstrong, LeAnn B. Norris, Charles L. Bennett. (2011) A probable serotonin syndrome complicating a routine screening colonoscopy procedure. Community Oncology 8:1, 41-42
     

119. 119

     Stania A. Dejesus, Vanessa A. Diaz, Wanda C. Gonsalves, Peter J. Carek. (2011) Identification and Treatment of Depression in Minority Populations. The International Journal of Psychiatry in Medicine 42:1, 69-83
     

120. 120

     Julie Hauer, Helen Wells O'Brien. Neurologic Diseases. In: Textbook of Interdisciplinary Pediatric Palliative Care. Elsevier, 2011:408-427.
     

121. 121

     Hiroyuki Kinoshita, Takuya Ohkubo, Mutsuko Yasuda, Fumiatsu Yakushiji. (2011) Serotonin syndrome induced by dextromethorphan (Medicon) administrated at the conventional dose. Geriatrics & Gerontology International 11:1, 121-122
     

122. 122

     Robin Steinberg-Epstein, Teri Book, Sharon B. Wigal. (2011) Controversies Surrounding Pediatric Psychopharmacology. Advances in Pediatrics 58:1, 153-179
     

123. 123

     B M Verdel, P C Souverein, S D Meenks, E R Heerdink, H G M Leufkens, T C G Egberts. (2011) Use of Serotonergic Drugs and the Risk of Bleeding. Clinical Pharmacology & Therapeutics 89:1, 89-96
     

124. 124

     Hans Rollema, Gary G. Wilson, Theodore C. Lee, Joost H.A. Folgering, Gunnar Flik. (2011) Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex. Neurochemistry International 58:1, 78-84
     

125. 125

     John W. Kreit. Antidepressant Drug Overdose. In: Textbook of Critical Care. Elsevier, 2011:1303-1307.
     

126. 126

     Katherine A. O'Donnell, Michele Burns Ewald. Poisonings. In: Nelson Textbook of Pediatrics. Elsevier, 2011:250-270.
     

127. 127

     Murat Oz, Dietrich E. Lorke, Mohammed Hasan, George A. Petroianu. (2011) Cellular and molecular actions of Methylene Blue in the nervous system. Medicinal Research Reviews 31:1, 93-117
     

128. 128

     Nicole C. Bouchard, Lewis S. Nelson. Opioids. In: Textbook of Critical Care. Elsevier, 2011:1354-1361.
     

129. 129

     I. Vogel Kahmann, W. Ruppen, G. Lurati Buse, D.A. Tsakiris, M. Bruggisser. (2011) Langzeitmedikation und perioperatives Management. Der Internist 52:1, 89-98
     

130. 130

     Debbie Steele, Norman L. Keltner, Teena M. McGuiness. (2011) Are Neuroleptic Malignant Syndrome and Serotonin Syndrome the Same Syndrome?. Perspectives in Psychiatric Care 47:1, 58-62
     

131. 131

     Jonathan R. Stevens, Maurizio Fava, Jerrold F. Rosenbaum, Jonathan E. Alpert. Psychopharmacology in the Medical Setting. In: Massachusetts General Hospital Handbook of General Hospital Psychiatry. Elsevier, 2011:441-466.
     

132. 132

     Ashley N. Webb, Prashant Joshi. Toxidromes and Their Treatment. In: Pediatric Critical Care. Elsevier, 2011:1451-1462.
     

133. 133

     Alan D. Woolf. Principles of Toxin Assessment and Screening. In: Pediatric Critical Care. Elsevier, 2011:1441-1450.
     

134. 134

     Lindsay Murray, Frank Daly, Mark Little, Mike Cadogan. Specific considerations. In: Toxicology Handbook. Elsevier, 2011:35-126.
     

135. 135

     B. Mégarbane. (2011) Présentation clinique des principales intoxications et approche par les toxidromes. Réanimation 21:S2, 482-493
     

136. 136

     Andrew A. Monte, Ryan Chuang, Michael Bodmer. (2010) Dextromethorphan, chlorphenamine and serotonin toxicity: case report and systematic literature review. British Journal of Clinical Pharmacology 70:6, 794-798
     

137. 137

     Amy C. Go, Larry K. Golightly, Gerard R. Barber, Michelle A. Barron. (2010) Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment. Drug Metabolism and Drug Interactions 25:1-4, 41-47
     

138. 138

     Bhawana Arora, Nirupama Kannikeswaran. (2010) The serotonin syndrome—the need for physician’s awareness. International Journal of Emergency Medicine 3:4, 373-377
     

139. 139

     J. Soar, G.D. Perkins, G. Abbas, A. Alfonzo, A. Barelli, J.J.L.M. Bierens, H. Brugger, C.D. Deakin, J. Dunning, M. Georgiou, A.J. Handley, D.J. Lockey, P. Paal, C. Sandroni, K.-C. Thies, D.A. Zideman, J.P. Nolan. (2010) Kreislaufstillstand unter besonderen Umständen: Elektrolytstörungen, Vergiftungen, Ertrinken, Unterkühlung, Hitzekrankheit, Asthma, Anaphylaxie, Herzchirurgie, Trauma, Schwangerschaft, Stromunfall. Notfall + Rettungsmedizin 13:7, 679-722
     

140. 140

     Andrew A. Monte, Javier C. Waksman. (2010) Chronic Olanzapine, Serotonin Receptors, and Subsequent Serotonin Toxicity. Journal of Clinical Psychopharmacology 30:5, 628-629
     

141. 141

     Swapna Krishnamoorthy, Zhiyuan Ma, Gongliang Zhang, Jianning Wei, Sidney B. Auerbach, Rui Tao. (2010) Involvement of 5-HT2A Receptors in the Serotonin (5-HT) Syndrome caused by Excessive 5-HT Efflux in Rat Brain. Basic & Clinical Pharmacology & Toxicology 107:4, 830-841
     

142. 142

     Jasmeet Soar, Gavin D. Perkins, Gamal Abbas, Annette Alfonzo, Alessandro Barelli, Joost J.L.M. Bierens, Hermann Brugger, Charles D. Deakin, Joel Dunning, Marios Georgiou, Anthony J. Handley, David J. Lockey, Peter Paal, Claudio Sandroni, Karl-Christian Thies, David A. Zideman, Jerry P. Nolan. (2010) European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: Electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation 81:10, 1400-1433
     

143. 143

     Senaka Rajapakse, Lakshan Abeynaike, Thanushi Wickramarathne. (2010) Venlafaxine-Associated Serotonin Syndrome Causing Severe Rhabdomyolysis and Acute Renal Failure in a Patient With Idiopathic Parkinson Disease. Journal of Clinical Psychopharmacology 30:5, 620-622
     

144. 144

     Ladan Zand, Scott J. Hoffman, Mark A. Nyman. (2010) 74-Year-Old Woman With New-Onset Myoclonus. Mayo Clinic Proceedings 85:10, 955-958
     

145. 145

     Andrew J. Muzyk, Rebekah J. Jakel, Xavier Preud’homme. (2010) Serotonin Syndrome After a Massive Overdose of Controlled-Release Paroxetine. Psychosomatics 51:5, 437-442
     

146. 146

     August Heidland, Katarina Sebekova, André Klassen, Miklós Palkovits. (2010) Mechanisms of Acute Uremic Encephalopathy: Early Activation of Fos and Fra-2 Gene Products in Different Nuclei/Areas of the Rat Brain. Journal of Renal Nutrition 20:5, S44-S50
     

147. 147

     Bernhard Iglseder, Eva Mann. (2010) Delir – akuter Verwirrtheitszustand: Diagnostik, Prävention und Therapie. Wiener klinische Wochenschrift Education 5:2, 95-106
     

148. 148

     Richard Hellman, Paul Ciechanowski. Diabetes and Depression: Management in Ordinary Clinical Conditions. In: Depression and Diabetes. John Wiley & Sons, Ltd, 2010:109-141.
     

149. 149

     James L. Young, Douglas Rund. (2010) Psychiatric Considerations in Patients with Decreased Levels of Consciousness. Emergency Medicine Clinics of North America 28:3, 595-609
     

150. 150

     Suzan Coster, Mirjam H.M. Visser, Daan J. Touw, Paul W. Wirtz. (2010) Serotonin Syndrome With Sertraline and Indomethacin. Journal of Clinical Psychopharmacology 30:4, 468-470
     

151. 151

     Timothy J. Meehan, Sean M. Bryant, Steven E. Aks. (2010) Drugs of Abuse: The Highs and Lows of Altered Mental States in the Emergency Department. Emergency Medicine Clinics of North America 28:3, 663-682
     

152. 152

     Christina L. Rim, Michael J. Gitlin. (2010) Ziprasidone, Monoamine Oxidase Inhibitors, and the Serotonin Syndrome. Journal of Clinical Psychopharmacology 30:4, 470-471
     

153. 153

     Zachary Berrens, Jessica Lammers, Christopher White. (2010) Rhabdomyolysis After LSD Ingestion. Psychosomatics 51:4, 356-356.e3
     

154. 154

     Carlos H. Rojas-Fernandez, Lisa J. Miller, Cheryl A. Sadowski. (2010) Considerations in the Treatment of Geriatric Depression. Research in Gerontological Nursing 3:3, 176-186
     

155. 155

     Christopher P Alderman, Dasha Loutchkina, Anita C Abarno. (2010) Psychotropic drug safety issues: continuing vigilance is needed. Expert Review of Clinical Pharmacology 3:4, 427-432
     

156. 156

     W. Warburton, C. Hertzman, T. F. Oberlander. (2010) A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatrica Scandinavica 121:6, 471-479
     

157. 157

     M. Reich, D. Lefebvre-Kuntz. (2010) Antidépresseurs sérotoninergiques et antalgiques opiacés : une association parfois « douloureuse » ! À propos d’un cas clinique. L'Encéphale 36, D119-D123
     

158. 158

     Elizabeth L. Thorpe, Anthony F. Pizon, Michael J. Lynch, Jessica Boyer. (2010) Bupropion Induced Serotonin Syndrome: A Case Report. Journal of Medical Toxicology 6:2, 168-171
     

159. 159

     Pei-Yin Lin, Chen-Jee Hong, Shih-Jen Tsai. (2010) Serotonin syndrome caused by ziprasidone alone. Psychiatry and Clinical Neurosciences 64:3, 338-339
     

160. 160

     Karen J. McAllen, David R. Schwartz. (2010) Adverse drug reactions resulting in hyperthermia in the intensive care unit. Critical Care Medicine 38, S244-S252
     

161. 161

     Randolph W. Evans, Stewart J. Tepper, Robert E. Shapiro, Christina Sun-Edelstein, Gretchen E. Tietjen. (2010) The FDA Alert on Serotonin Syndrome With Use of Triptans Combined With Selective Serotonin Reuptake Inhibitors or Selective Serotonin-Norepinephrine Reuptake Inhibitors: American Headache Society Position Paper. Headache: The Journal of Head and Face Pain 50:6, 1089-1099
     

162. 162

     Bernhard Iglseder, Peter Dovjak, Ursula Benvenuti-Falger, Birgit Böhmdorfer, Monika Lechleitner, Ronald Otto, Regina E. Roller, Ulrike Sommeregger, Markus Gosch. (2010) Medikamenten-induzierte Delirien älterer Menschen. Wiener Medizinische Wochenschrift 160:11-12, 281-285
     

163. 163

     Bradley K.W. Ng, Andrew J.D. Cameron. (2010) The Role of Methylene Blue in Serotonin Syndrome: A Systematic Review. Psychosomatics 51:3, 194-200
     

164. 164

     J.L. Pilgrim, D. Gerostamoulos, Olaf H. Drummer. (2010) Deaths involving serotonergic drugs. Forensic Science International 198:1-3, 110-117
     

165. 165

     Young-Min Park, Yeon-Kyung Jung. (2010) Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34:4, 719-720
     

166. 166

     Julie Hauer. (2010) Identifying and Managing Sources of Pain and Distress in Children with Neurological Impairment. Pediatric Annals 39:4, 198-205
     

167. 167

     Alan H. Yee, Eelco F. M. Wijdicks. (2010) A Perfect Storm in the Emergency Department. Neurocritical Care 12:2, 258-260
     

168. 168

     S. Vesperini, F. Papetti, D. Pringuey. (2010) Existe-t-il un lien entre catatonie et syndrome malin des neuroleptiques ?. L'Encéphale 36:2, 105-110
     

169. 169

     (2010) Mental health nursing is not for sale: rethinking nursing's relationship with the pharmaceutical industry. Journal of Psychiatric and Mental Health Nursing 17:2, 172-177
     

170. 170

     Sven Armbrust, Werner Nikischin, Gertrud Rochholz, Cornelia Franzelius, Andreas Bielstein, Hans-Heiner Kramer. (2010) Hypothermia in a combined intoxication with doxepin and moclobemide in an adolescent. Forensic Science International 195:1-3, e1-e3
     

171. 171

     P. Ken Gillman. (2010) Triptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review. Headache: The Journal of Head and Face Pain 50:2, 264-272
     

172. 172

     Christian Settle Altman, Mohammed Farid Jahangiri. (2010) Serotonin Syndrome in the Perioperative Period. Anesthesia & Analgesia 110:2, 526-528
     

173. 173

     Daniel M. Lugassy, Robert S. Hoffman, Noemie Chessex. (2010) In Response to van Gorp F. et al. Annals of Emergency Medicine 55:1, 128-129
     

174. 174

     Amer A. Alkhatib, Kathryn A. Peterson, Ashok K. Tuteja. (2010) Serotonin Syndrome as a Complication of Fentanyl Sedation During Esophagogastroduodenoscopy. Digestive Diseases and Sciences 55:1, 215-216
     

175. 175

     Roy Ann Sherrod, Angela Collins, Stephanie Wynn, Monika Gragg. (2010) Dissecting Dementia, Depression, and Drug Effects in Older Adults. Journal of Psychosocial Nursing and Mental Health Services 48:1, 39-47
     

176. 176

     Arthur Saniotis, Rod Irvine. (2010) Climate change and the possible health effects on older Australians. Australian Journal of Primary Health 16:3, 217
     

177. 177

     Elisabeth F. Bilden. Antidepressants. In: Rosen's Emergency Medicine – Concepts and Clinical Practice. Elsevier, 2010:1964-1977.
     

178. 178

     Ken Kulig, Louis J. Ling. General Approach to the Poisoned Patient. In: Rosen's Emergency Medicine – Concepts and Clinical Practice. Elsevier, 2010:1942-1947.
     

179. 179

     Harvey S. Singer, Jonathan W. Mink, Donald L. Gilbert, Joseph Jankovic. Drug-Induced Movement Disorders in Children. In: Movement Disorders in Childhood. Elsevier, 2010:231-241.
     

180. 180

     Harvey S. Singer, Jonathan W. Mink, Donald L. Gilbert, Joseph Jankovic. Myoclonus. In: Movement Disorders in Childhood. Elsevier, 2010:110-128.
     

181. 181

     Gregory L. Fricchione, Anne F. Gross, Jeff C. Huffman, George Bush, Theodore A. Stern. Catatonia, Neuroleptic Malignant Syndrome, and Serotonin Syndrome. In: Massachusetts General Hospital Handbook of General Hospital Psychiatry. Elsevier, 2010:273-288.
     

182. 182

     Alister Vale, Sally Bradberry. Clinical Toxicology. In: General and Applied Toxicology. John Wiley & Sons, Ltd, 2009.
     

183. 183

     Douglas A Drossman. (2009) Beyond Tricyclics: New Ideas for Treating Patients With Painful and Refractory Functional Gastrointestinal Symptoms. The American Journal of Gastroenterology 104:12, 2897-2902
     

184. 184

     Pei-Tsung Liu, Vivian Argento, Beata Skudlarska, Marina Blagodatny. (2009) SEROTONIN SYNDROME IN AN OCTOGENARIAN AFTER SWITCH FROM FLUOXETINE TO DULOXETINE. Journal of the American Geriatrics Society 57:12, 2384-2384
     

185. 185

     Delmar D. Short, Joanne M. Hawley, Maureen F. McCarthy. (2009) Management of Schizophrenia with Medical Disorders: Cardiovascular, Pulmonary, and Gastrointestinal. Psychiatric Clinics of North America 32:4, 759-773
     

186. 186

     Clementine Nordon, Karin Martin-Latry, Laurence de Roquefeuil, Philippe Latry, Bernard Bégaud, Bruno Falissard, Frederic Rouillon, Helene Verdoux. (2009) Risk of Death Related to Psychotropic Drug Use in Older People During the European 2003 Heatwave: A Population-Based Case–Control Study. The American Journal of Geriatric Psychiatry 17:12, 1059-1067
     

187. 187

     Theresa J. Inott. (2009) The dark side of SSRIs. Nursing Management (Springhouse) 40:11, 44-46
     

188. 188

     Jonathan Lee, Lauren Franz, Harold W. Goforth. (2009) Serotonin Syndrome in a Chronic-Pain Patient Receiving Concurrent Methadone, Ciprofloxacin, and Venlafaxine. Psychosomatics 50:6, 638-639
     

189. 189

     CATE WALLACE, TONY GALLOWAY, REBECCA MCKETIN, ERIN KELLY, JOHN LEARY. (2009) Methamphetamine use, dependence and treatment access in rural and regional North Coast of New South Wales, Australia. Drug and Alcohol Review 28:6, 592-599
     

190. 190

     David R.P. Guay. (2009) Is Tapentadol an Advance on Tramadol?. The Consultant Pharmacist 24:11, 833-840
     

191. 191

     P. P. Pandharipande, A. Morandi, J. R. Adams, T. D. Girard, J. L. Thompson, A. K. Shintani, E. Wesley Ely. (2009) Plasma tryptophan and tyrosine levels are independent risk factors for delirium in critically ill patients. Intensive Care Medicine 35:11, 1886-1892
     

192. 192

     Johanna Hilli, Tuomas Korhonen, Kari Laine. (2009) Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33:8, 1526-1532
     

193. 193

     Geoffrey Pollack, Aron Pollack, Joel Delfiner, John Fernandez. (2009) Parathyroid surgery and methylene blue: A review with guidelines for safe intraoperative use. The Laryngoscope 119:10, 1941-1946
     

194. 194

     E. Beubler. (2009) Arzneimittelinteraktionen im Alter. Wechselwirkungen werden meist ignoriert. focus neurogeriatrie 3:3, 6-9
     

195. 195

     Raymond W. Lam, Sidney H. Kennedy, Sophie Grigoriadis, Roger S. McIntyre, Roumen Milev, Rajamannar Ramasubbu, Sagar V. Parikh, Scott B. Patten, Arun V. Ravindran. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. Journal of Affective Disorders 117, S26-S43
     

196. 196

     Donald C. Vinh, Ethan Rubinstein. (2009) Linezolid: a review of safety and tolerability. Journal of Infection 59, S59-S74
     

197. 197

     Juan Carlos Gómez-Esteban, Joseba Barcena, Maribel Forcadas, Johanne Somme, Marta Agundez, Beatriz Tijero, Juan J. Zarranz. (2009) Neuroleptic Malignant Syndrome and Serotonin Syndrome in a Female Patient. Clinical Neuropharmacology 32:5, 299-300
     

198. 198

     S.-L. Guo, T.-J. Wu, C.-C. Liu, C.-C. Ng, C.-C. Chien, H.-L. Sun. (2009) Meperidine-induced serotonin syndrome in a susceptible patient. British Journal of Anaesthesia 103:3, 369-370
     

199. 199

     Katherine A. O'Donnell, Michele Burns Ewald. (2009) Huffing and Puffing to Lose Weight. Pediatric Emergency Care 25:9, 605-607
     

200. 200

     Neil E. I. Langlois. (2009) Sudden adult death. Forensic Science, Medicine, and Pathology 5:3, 210-232
     

201. 201

     Gongliang Zhang, Swapna Krishnamoorthy, Zhiyuan Ma, Nick P. Vukovich, Xupei Huang, Rui Tao. (2009) Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome. European Journal of Pharmacology 615:1-3, 66-75
     

202. 202

     C. Schwiebert, C. Irving, P. K. Gillman. (2009) Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity. Anaesthesia 64:8, 924-924
     

203. 203

     E. Montané, A. Barriocanal, I. Isern, T. Parajon, J. Costa. (2009) Multiple drug interactions - induced serotonin syndrome: a case report. Journal of Clinical Pharmacy and Therapeutics 34:4, 485-487
     

204. 204

     Michael Rowley, Kevin Riutort, David Shapiro, John Casler, Emir Festic, William D. Freeman. (2009) Methylene Blue-Associated Serotonin Syndrome: A ‘Green’ Encephalopathy After Parathyroidectomy. Neurocritical Care 11:1, 88-93
     

205. 205

     Ken P. Gillman, Shannon Pearce, Nasiya Ahmed, Grace M. Varas. (2009) Lessons Continue: Serotonin Toxicity. The Consultant Pharmacist 24:7, 474-476
     

206. 206

     Priya Sampathkumar, Lisa A. Drage, David P. Martin. (2009) Herpes Zoster: Query and Concern–Reply–I. Mayo Clinic Proceedings 84:7, 663-664
     

207. 207

     Nina Boucher, Gideon Koren, Louise Beaulac-Baillargeon. (2009) Maternal Use of Venlafaxine Near Term: Correlation Between Neonatal Effects and Plasma Concentrations. Therapeutic Drug Monitoring 31:3, 404-409
     

208. 208

     Eric J. Brantley, Jamieson V. Cohn, Kavita M. Babu. (2009) Case files of the Program in Medical Toxicology at Brown University: Amantadine withdrawal and the neuroleptic malignant syndrome. Journal of Medical Toxicology 5:2, 92-98
     

209. 209

     Ana Cristina Bandrés Liso, Carla Toyas Miazza. (2009) Cuadro confusional y alucinaciones por interacción entre rasagilina y escitalopram. Farmacia Hospitalaria 33:3, 173-175
     

210. 210

     Philip J. Mease, Ernest H. Choy. (2009) Pharmacotherapy of Fibromyalgia. Rheumatic Disease Clinics of North America 35:2, 359-372
     

211. 211

     Kurt Kroenke, Erin E. Krebs, Matthew J. Bair. (2009) Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. General Hospital Psychiatry 31:3, 206-219
     

212. 212

     P. Ken Gillman. (2009) Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity?. The American Journal of Emergency Medicine 27:4, 509-510
     

213. 213

     Chad S. Boomershine, Leslie J. Crofford. (2009) A symptom-based approach to pharmacologic management of fibromyalgia. Nature Reviews Rheumatology 5:4, 191-199
     

214. 214

     Randolph W. Evans. (2009) Migraine: A Question and Answer Review. Medical Clinics of North America 93:2, 245-262
     

215. 215

     (2009) Correspondence. Australian and New Zealand Journal of Psychiatry 43:6, 579-582
     

216. 216

     Karin Reuter-Rice. (2009) Ecstasy in the Emergency Department: MDMA Ingestion. Journal of Pediatric Health Care 23:1, 49-53
     

217. 217

     Shannon Pearce, Nasiya Ahmed, Grace M. Varas. (2009) <b>A Case Study of Delayed Serotonin Syndrome: Lessons Learned</b>. The Consultant Pharmacist 24:1, 64-68
     

218. 218

     Alfredo Bianchi. HEADACHE. In: Pharmacology and Therapeutics. Elsevier, 2009:719-742.
     

219. 219

     Zeina Chemali, Lama M. Chahine, Gregory Fricchione. (2009) The Use of Selective Serotonin Reuptake Inhibitors in Elderly Patients. Harvard Review of Psychiatry 17:4, 242-253
     

220. 220

     J. Freijo Guerrero, L. Tardón Ruiz de Gauna, J.J. Gómez, L. Aguilera Celorrio. (2009) Síndrome serotoninérgico en la unidad de cuidados críticos tras administración de mirtazapina. Revista Española de Anestesiología y Reanimación 56:8, 515-516
     

221. 221

     Beatriz Arbaizar, Inés Gómez-Acebo, Javier Llorca. (2008) Postural induced-tremor in psychiatry. Psychiatry and Clinical Neurosciences 62:6, 638-645
     

222. 222

     Timothy Kleinig, Philip Thompson. A woman with recurrent ataxia and facial myoclonus. In: Movement Disorders. CRC Press, 2008:171-173.
     

223. 223

     Giuseppe La Regina, Romano Silvestri, Valerio Gatti, Antonio Lavecchia, Ettore Novellino, Olivia Befani, Paola Turini, Enzo Agostinelli. (2008) Synthesis, structure–activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorganic & Medicinal Chemistry 16:22, 9729-9740
     

224. 224

     Luke T. Day, Rebecca K. Jeanmonod. (2008) Serotonin syndrome in a patient taking Lexapro and Flexeril: a case report. The American Journal of Emergency Medicine 26:9, 1069.e1-1069.e3
     

225. 225

     Hervé Tixier, Cecile Feyeux, Sophie Girod, Ségoléne Thouvenot, Mathieu Morisse, Serge Douvier, Paul Sagot. (2008) Acute voluntary intoxication with selective serotonin reuptake inhibitors during the third trimester of pregnancy: therapeutic management of mother and fetus. American Journal of Obstetrics and Gynecology 199:5, e9-e12
     

226. 226

     Scott Strassels, Ewan D McNicol, Marie Belle D Francia, Jodie Pepin, Kenneth C Jackson, Scott Strassels. Meperidine (pethidine) for treatment of postoperative pain in adults. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008.
     

227. 227

     Felicia A. Smith, Curtis W. Wittmann, Theodore A. Stern. (2008) Medical Complications of Psychiatric Treatment. Critical Care Clinics 24:4, 635-656
     

228. 228

     Donald L. Gilbert. (2008) Drug-induced Movement Disorders in Children. Annals of the New York Academy of Sciences 1142:1, 72-84
     

229. 229

     Clare Ringland, Andrea Mant, Patricia McGettigan, Philip Mitchell, Christopher Kelman, Nicholas Buckley, Sallie-Anne Pearson. (2008) Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. British Journal of Clinical Pharmacology
     

230. 230

     Brian Szakaly, Robert Strauss. (2008) Serotonin Syndrome in the Oral and Maxillofacial Surgery Office: A Review of the Literature and Report of a Case. Journal of Oral and Maxillofacial Surgery 66:9, 1949-1952
     

231. 231

     Christina Sun-Edelstein, Stewart J Tepper, Robert E Shapiro. (2008) Drug-induced serotonin syndrome: a review. Expert Opinion on Drug Safety 7:5, 587-596
     

232. 232

     Derek Isenberg, Stella C. Wong, John A. Curtis. (2008) Serotonin syndrome triggered by a single dose of suboxone. The American Journal of Emergency Medicine 26:7, 840.e3-840.e5
     

233. 233

     (2008) More on Serotonin Syndrome Associated with Triptan Monotherapy. New England Journal of Medicine 359:8, 870-871
     Free Full Text

234. 234

     Jacquelyn L. Bainbridge, Robert Lee Page, J. Mark Ruscin. (2008) Elucidating the Mechanism of Action and Potential Interactions of MAO-B Inhibitors. Neurologic Clinics 26:3, 85-96
     

235. 235

     Tomer T. Levin, Alberto Cortes-Ladino, Mark Weiss, M. Lia Palomba. (2008) Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion. General Hospital Psychiatry 30:4, 372-377
     

236. 236

     Zhiyuan Ma, Gongliang Zhang, Chris Jenney, Swapna Krishnamoorthy, Rui Tao. (2008) Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats. European Journal of Pharmacology 588:2-3, 198-206
     

237. 237

     P.-O. Lang, Y. Hasso, H. Hilleret, N. Vogt-Ferrier. (2008) Syndrome sérotoninergique consécutif à l’association d’escitalopram et de cyclosporine chez une patiente de 84 ans. La Revue de Médecine Interne 29:7, 583-586
     

238. 238

     Tina Q Tan, Ram Yogev. (2008) Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent. Expert Review of Clinical Pharmacology 1:4, 479-489
     

239. 239

     Bradley K. W. Ng, Andrew J. D. Cameron, Rhea Liang, Habib Rahman. (2008) Serotonin syndrome following methylene blue infusion during parathyroidectomy: A case report and literature review. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 55:1, 36-41
     

240. 240

     L. F. MOHAMMAD-ZADEH, L. MOSES, S. M. GWALTNEY-BRANT. (2008) Serotonin: a review. Journal of Veterinary Pharmacology and Therapeutics 31:3, 187-199
     

241. 241

     Nina Boucher, Aida Bairam, Louise Beaulac-Baillargeon. (2008) A New Look at the Neonate's Clinical Presentation After In Utero Exposure to Antidepressants in Late Pregnancy. Journal of Clinical Psychopharmacology 28:3, 334-339
     

242. 242

     Ai-Ming Yu. (2008) Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions. The AAPS Journal 10:2, 242-253
     

243. 243

     Soldin , Offie P. , , Tonning , Joseph M. , . (2008) Serotonin Syndrome Associated with Triptan Monotherapy. New England Journal of Medicine 358:20, 2185-2186
     Free Full Text

244. 244

     Rachel P. Riechelmann, Camilla Zimmermann, Sheray N. Chin, Lisa Wang, Aoife O'Carroll, Sanaz Zarinehbaf, Monika K. Krzyzanowska. (2008) Potential Drug Interactions in Cancer Patients Receiving Supportive Care Exclusively. Journal of Pain and Symptom Management 35:5, 535-543
     

245. 245

     Yael Dvir, Patrick Smallwood. (2008) Serotonin syndrome: a complex but easily avoidable condition. General Hospital Psychiatry 30:3, 284-287
     

246. 246

     Samuray Ozdemir, Irem Yalug, Ahmet Tamer Aker. (2008) Serotonin syndrome associated with sertraline monotherapy at therapeutic doses. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32:3, 897-898
     

247. 247

     Motoyasu Ishii, Yoshitaka Tatsuzawa, Aihide Yoshino, Soichiro Nomura. (2008) Serotonin syndrome induced by augmentation of SSRI with methylphenidate. Psychiatry and Clinical Neurosciences 62:2, 246-246
     

248. 248

     Allan V. Kalueff, Justin L. LaPorte, Dennis L. Murphy. (2008) Perspectives on genetic animal models of serotonin toxicity. Neurochemistry International 52:4-5, 649-658
     

249. 249

     Walter Glannon. (2008) Psychopharmacological Enhancement. Neuroethics 1:1, 45-54
     

250. 250

     (2008) Use of Antidepressants in Nursing Home Residents. The Consultant Pharmacist 23:3, 231-234
     

251. 251

     Wai-Song Yeung. (2008) Suanzaorentang and Serotonin Syndrome. Journal of Clinical Psychopharmacology 28:1, 113-114
     

252. 252

     T.P. Jürgens, E. Leinisch, H.J. Koch. (2008) Eine klinische Herausforderung. Der Schmerz 22:S1, 11-16
     

253. 253

     Giovanna Poce, Giovanni Zappia, Giulio Cesare Porretta, Bruno Botta, Mariangela Biava. (2008) New oxazolidinone derivatives as antibacterial agents with improved activity. Expert Opinion on Therapeutic Patents 18:2, 97-121
     

254. 254

     P. K. Das, D. I. Warkentin, R. Hewko, D. L. Forrest. (2008) Serotonin Syndrome after Concomitant Treatment with Linezolid and Meperidine. Clinical Infectious Diseases 46:2, 264-265
     

255. 255

     Aliaksei Pustavoitau, Robert D. Stevens. (2008) Mechanisms of Neurologic Failure in Critical Illness. Critical Care Clinics 24:1, 1-24
     

256. 256

     Sharon G. Childs. (2008) Serotonergic Thrombocytopathy and Its Effects on Platelets During Orthopaedic Surgery. Orthopaedic Nursing 27:1, 42-47
     

257. 257

     Fran M. Gengo. Pharmacological Principles in Treating Neurological Disease. In: Neurology in Clinical Practice. Elsevier, 2008:859-897.
     

258. 258

     T F Oberlander, R J Bonaguro, S Misri, M Papsdorf, C J D Ross, E M Simpson. (2008) Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Molecular Psychiatry 13:1, 65-73
     

259. 259

     Brian Draper, Karen Berman. (2008) Tolerability of Selective Serotonin Reuptake Inhibitors. Drugs & Aging 25:6, 501-519
     

260. 260

     Roberta L Hines, Katherine E Marschall. Psychiatric Disease/ Substance Abuse/Drug Overdose. In: Stoelting's Anesthesia and Co-Existing Disease. Elsevier, 2008:533-555.
     

261. 261

     Kenneth Alper. Do Antidepressants Improve or Worsen Seizures in Patients with Epilepsy?. In: Psychiatric Controversies in Epilepsy. Elsevier, 2008:255-267.
     

262. 262

     Bénédicte Verdu, Isabelle Decosterd, Thierry Buclin, Friedrich Stiefel, Alexandre Berney. (2008) Antidepressants for the Treatment of Chronic Pain. Drugs 68:18, 2611-2632
     

263. 263

     B. Mégarbane, F. Baud. (2008) Intossicazioni acute da farmaci. EMC - AKOS - Trattato di Medicina 10:3, 1-10
     

264. 264

     Jonathan E. Alpert. Drug-Drug Interactions in Psychopharmacology. In: Massachusetts General Hospital Comprehensive Clinical Psychiatry. Elsevier, 2008:687-704.
     

265. 265

     Gregory L. Fricchione, Jeff C. Huffman, George Bush, Theodore A. Stern. Catatonia, Neuroleptic Malignant Syndrome, and Serotonin Syndrome. In: Massachusetts General Hospital Comprehensive Clinical Psychiatry. Elsevier, 2008:761-771.
     

266. 266

     Janice L. Zimmerman, Maria Rudis. Poisonings. In: Critical Care Medicine. Elsevier, 2008:1453-1474.
     

267. 267

     David Myland Kaufman. Trastornos musculares. In: Neurología clínica para psiquiatras. Elsevier, 2008:87-100.
     

268. 268

     Peter De Paepe, Paul A. Calle, Walter A. Buylaert. Coma Induced by Intoxication. Elsevier, 2008:175-191.
     

269. 269

     B. Mégarbane, F. Baud. (2008) Intoxications médicamenteuses aiguës. EMC - Traité de médecine AKOS 3:2, 1-10
     

270. 270

     S.-A. Pearson, C. Ringland, C. Kelman, A. Mant, J. Lowinger, H. Stark, G. Nichol, R. Day, D. Henry. (2007) Patterns of analgesic and anti-inflammatory medicine use by Australian veterans. Internal Medicine Journal 37:12, 798-805
     

271. 271

     N Bonetto, L Santelli, L Battistin, A Cagnin. (2007) Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. Cephalalgia 27:12, 1421-1423
     

272. 272

     Unützer , Jürgen , . (2007) Late-Life Depression. New England Journal of Medicine 357:22, 2269-2276
     Full Text

273. 273

     Michael Ganetsky, Kavita M. Babu, Edward W. Boyer. (2007) Serotonin Syndrome in Dextromethorphan Ingestion Responsive to Propofol Therapy. Pediatric Emergency Care 23:11, 829-831
     

274. 274

     Howard S. Kirshner. (2007) Delirium: A focused review. Current Neurology and Neuroscience Reports 7:6, 479-482
     

275. 275

     (2007) Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders. Journal of the American Academy of Child & Adolescent Psychiatry 46:11, 1503-1526
     

276. 276

     Jessica Robinson-Papp, David M. Simpson. (2007) Safety Profile of Treatment in Diabetic Peripheral Neuropathic Pain. Pain Medicine 8:s2 Duloxetine, S43-S49
     

277. 277

     Julia Kaci, David T. Lowenthal, Scott Lagasse. (2007) Clinical physiology and pharmacology conference: rhabdomyolysis and serotonin syndrome in an elderly patient. International Urology and Nephrology 39:3, 985-987
     

278. 278

     SEROTONIN SYNDROME. In: Poisoning and Toxicology Handbook, Fourth Edition. CRC Press, 2007:1290-1291.
     

279. 279

     John H.J.M. Meertens, Wilma E. Monteban-Kooistra, Jack J.M. Ligtenberg, Jaap E. Tulleken, Jan G. Zijlstra. (2007) Severe Hypoglycemia Following Venlafaxine Intoxication. Journal of Clinical Psychopharmacology 27:4, 414-415
     

280. 280

     Masashi Narita, Brian T Tsuji, Victor L Yu. (2007) Linezolid-Associated Peripheral and Optic Neuropathy, Lactic Acidosis, and Serotonin Syndrome. Pharmacotherapy 27:8, 1189-1197
     

281. 281

     Sokratis G. Papageorgiou, Theodoros Kontaxis, Alexandra Antelli, Nikolaos Kalfakis. (2007) Exacerbation of Myoclonus by Memantine in a Patient With Alzheimer Disease. Journal of Clinical Psychopharmacology 27:4, 407-408
     

282. 282

     Manju T. Beier, Caren McHenry Martin. (2007) <b>Gradual Dose Reduction and Medication Tapering: A Clinical Perspective</b>. The Consultant Pharmacist 22:8, 628-644
     

283. 283

     E. M. Altman, G. H. Manos. (2007) Serotonin Syndrome Associated With Citalopram and Meperidine. Psychosomatics 48:4, 361-363
     

284. 284

     M.J. Bruscas Alijarde, L. de Benito Cordón, D. García Mateos, M. Ruiz Clemente, M.J. Hervás Laguna. (2007) Síndrome neuroléptico maligno y síndrome serotoninérgico: a propósito de dos casos. Revista Clínica Española 207:7, 374-375
     

285. 285

     Leah N. Squires, Kristen N. Talbot, Stanislav S. Rubakhin, Jonathan V. Sweedler. (2007) Serotonin catabolism in the central and enteric nervous systems of rats upon induction of serotonin syndrome. Journal of Neurochemistry 0:0, 070630082917006-???
     

286. 286

     Kevin C. Osterhoudt, Rakesh Mistry. (2007) A Boy With Tremor, Diaphoresis, and Altered Behavior. Pediatric Emergency Care 23:6, 419-421
     

287. 287

     A. V. Kalueff, M. A. Fox, P. S. Gallagher, D. L. Murphy. (2007) Hypolocomotion, anxiety and serotonin syndrome-like behavior contribute to the complex phenotype of serotonin transporter knockout mice. Genes, Brain and Behavior 6:4, 389-400
     

288. 288

     Lauren H Sansing, Erdem Tüzün, Melissa W Ko, Jennifer Baccon, David R Lynch, Josep Dalmau. (2007) A patient with encephalitis associated with NMDA receptor antibodies. Nature Clinical Practice Neurology 3:5, 291-296
     

289. 289

     Ruben HK Thanacoody. (2007) Serotonin syndrome. Adverse Drug Reaction Bulletin &amp;NA;:243, 931-934
     

290. 290

     Gabor Vari, Mace Beckson. (2007) Escitalopram-Associated Serotonin Toxicity. Journal of Clinical Psychopharmacology 27:2, 229-230
     

291. 291

     S. Ailawadhi, K.-W. Sung, L. A. Carlson, M. R. Baer. (2007) Serotonin syndrome caused by interaction between citalopram and fentanyl. Journal of Clinical Pharmacy and Therapeutics 32:2, 199-202
     

292. 292

     Jon R. Nash, David J. Nutt. Pharmacotherapy of Anxiety. In: Handbook of Contemporary Neuropharmacology. John Wiley & Sons, Inc., 2007.
     

293. 293

     Francisca Llinares-Tello, Salvador Escrivá-Moscardó, Francisco Martínez-Pastor, Pedro Martínez-Mascaraque. (2007) Probable síndrome serotoninérgico relacionado con la administración de paroxetina y tramadol. Medicina Clínica 128:11, 438-438
     

294. 294

     Khrista Boylan, Soledad Romero, Boris Birmaher. (2007) Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacology 191:1, 27-38
     

295. 295

     Bruce Potenza, Mark Greenberg, Lesley Wong, Andrea Dunkelman, Mayer Tenenhaus. Burn Injuries. In: Trauma. CRC Press, 2007:645-683.
     

296. 296

     Richard Clark, William Richardson, Tri Tong. Poisoning and Toxic Exposure. In: Trauma. CRC Press, 2007:591-617.
     

297. 297

     K. J. Looper. (2007) Potential Medical and Surgical Complications of Serotonergic Antidepressant Medications. Psychosomatics 48:1, 1-9
     

298. 298

     Pascal Fangio, Bernard De Jonghe, Corinne Appéré-De-Vecchi, Jean-Claude Lachérade, Jean-Pierre Terville, Hervé Outin, Joël Dagorn. (2007) Acute heart failure associated with venlafaxine poisoning. The American Journal of Emergency Medicine 25:2, 210-211
     

299. 299

     Edmund Silins, Jan Copeland, Paul Dillon. (2007) Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Australian and New Zealand Journal of Psychiatry 41:8, 649-655
     

300. 300

     S. K. Ballas. (2007) Current Issues in Sickle Cell Pain and Its Management. Hematology 2007:1, 97-105
     

301. 301

     I. In: Drugs for the Geriatric Patient. Elsevier, 2007:607-659.
     

302. 302

     T. In: Drugs for the Geriatric Patient. Elsevier, 2007:1166-1282.
     

303. 303

     Robert S. Gable. (2007) Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 102:1, 24-34
     

304. 304

     S. Nichole Feeney. Serotonin Syndrome. In: Pediatric Clinical Advisor. Elsevier, 2007:516-517.
     

305. 305

     Takeshi Terao, Takatoshi Hikichi. (2007) Serotonin syndrome in a case of depression with various somatic symptoms: The difficulty in differential diagnosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 31:1, 295-296
     

306. 306

     P. In: Drugs for the Geriatric Patient. Elsevier, 2007:930-1062.
     

307. 307

     Jeong-Min Kim, Soon-Tae Lee, Eun-Cheol Song, Keun-Hwa Jung, Dong-In Sinn, Hakjae Chung, Kon Chu, Manho Kim. (2007) Neurotoxic Syndrome Developed after Taking Sertraline and Risperidone. Journal of Clinical Neurology 3:3, 165
     

308. 308

     Temperature. In: Evidence-Based Physical Diagnosis. Elsevier, 2007:174-186.
     

309. 309

     Muscle Disorders. In: Clinical Neurology for Psychiatrists. Elsevier, 2007:87-110.
     

310. 310

     JEFFREY BRENT, ROBERT PALMER. Monoamine Oxidase Inhibitors and Serotonin Syndrome. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. Elsevier, 2007:561-577.
     

311. 311

     Andrew Miller, Andrew McKee, C. David Mazer. Sedation, Analgesia, and Related Topics. In: Cardiothoracic Critical Care. Elsevier, 2007:53-70.
     

312. 312

     MICHAEL W. SHANNON. Drug Interactions. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose. Elsevier, 2007:97-104.
     

313. 313

     Hideo H. Itabashi, John M. Andrews, Uwamie Tomiyasu, Stephanie S. Erlich, Lakshmanan Sathyavagiswaran. Responses of the central nervous system to acute hypoxic-ischemic injury and related conditions. In: Forensic Neuropathology. Elsevier, 2007:289-305.
     

314. 314

     P. Hausfater, B. Riou. (2007) Hyperthermie de l'adulte et coup de chaleur. EMC - Médecine d 'urgence 2:1, 1-12
     

315. 315

     Muscle Disorders. In: Clinical Neurology for Psychiatrists. Elsevier, 2007:87-110.
     

316. 316

     Lois Wonsun Choi-Kain, Harrison Graham Pope. (2007) “Atypical” Neuroleptic Malignant Syndrome and the Spectrum of Malignant Cerebrotoxic Syndromes. Harvard Review of Psychiatry 15:4, 181-186
     

317. 317

     Ilan A. Kerman, Cyrus Shabrang, Larry Taylor, Huda Akil, Stanley J. Watson. (2006) Relationship of presympathetic-premotor neurons to the serotonergic transmitter system in the rat brainstem. The Journal of Comparative Neurology 499:6, 882-896
     

318. 318

     Vanthida Huang, Justine S Gortney. (2006) Risk of Serotonin Syndrome with Concomitant Administration of Linezolid and Serotonin Agonists. Pharmacotherapy 26:12, 1784-1793
     

319. 319

     Mark T. Keegan, Daniel R. Brown, Alejandro A. Rabinstein. (2006) Serotonin Syndrome from the Interaction of Cyclobenzaprine with Other Serotoninergic Drugs. Anesthesia & Analgesia 103:6, 1466-1468
     

320. 320

     Eric Bush, Carol Miller, Irwin Friedman. (2006) A Case of Serotonin Syndrome and Mutism associated with Methadone. Journal of Palliative Medicine 9:6, 1257-1259
     

321. 321

     Thomas B. Strouse, Thomas N. Kerrihard, Charles A. Forscher, Philip Zakowski. (2006) Serotonin Syndrome Precipitated by Linezolid in a Medically Ill Patient on Duloxetine. Journal of Clinical Psychopharmacology 26:6, 681-683
     

322. 322

     J. J. Taylor, L. L. Estes, J. W. Wilson. (2006) Linezolid and Serotonergic Drug Interactions. Clinical Infectious Diseases 43:10, 1371-1371
     

323. 323

     Christophe Liberek, Jean-Michel Aubry, Patrick Baud. (2006) Manic Switch and Serotonin Syndrome with Venlafaxine-Lithium-Valproate Association. Thérapie 61:6, 531-533
     

324. 324

     S. Cassens, E. A. Nickel, M. Quintel, P. Neumann. (2006) Das Serotoninsyndrom. Der Anaesthesist 55:11, 1189-1196
     

325. 325

     P Paruchuri, D Godkar, D Anandacoomarswamy, K Sheth, S Niranjan. (2006) Rare Case of Serotonin Syndrome With Therapeutic Doses of Paroxetine. American Journal of Therapeutics 13:6, 550-552
     

326. 326

     Luis Felipe Flores-Suárez, María Elisa Vega-Memije, Caroline Chanussot-Deprez. (2006) Cutaneous Vasculitis During Selective Serotonin Reuptake Inhibitor Therapy. The American Journal of Medicine 119:10, e1-e3
     

327. 327

     David A. Brent, Boris Birmaher. (2006) Treatment-Resistant Depression in Adolescents: Recognition and Management. Child and Adolescent Psychiatric Clinics of North America 15:4, 1015-1034
     

328. 328

     MICHELE LABOTZ, TOBY K. WOLFF, KENNETH T. NAKASONE, IRIS F. KIMURA, RONALD K. HETZLER, ANDREW W. NICHOLS. (2006) Selective Serotonin Reuptake Inhibitors and Rhabdomyolysis after Eccentric Exercise. Medicine & Science in Sports & Exercise 38:9, 1539-1542
     

329. 329

     J. Adan-Manes, J. Novalbos, R. Lopez-Rodriguez, J. L. Ayuso-Mateos, F. Abad-Santos. (2006) Lithium and venlafaxine interaction: a case of serotonin syndrome. Journal of Clinical Pharmacy and Therapeutics 31:4, 397-400
     

330. 330

     H. Florence Kim, Michael J. Fisch. (2006) Antidepressant use in ambulatory cancer patients. Current Oncology Reports 8:4, 275-281
     

331. 331

     Jeremy J. Taylor, John W. Wilson, Lynn L. Estes. (2006) Linezolid and Serotonergic Drug Interactions: A Retrospective Survey. Clinical Infectious Diseases 43:2, 180-187
     

332. 332

     Diane P. Calello, Kevin C. Osterhoudt, Fred M. Henretig. (2006) New and Novel Antidotes in Pediatrics. Pediatric Emergency Care 22:7, 523-530
     

333. 333

     Frederick J. Stoddard, Craigan T. Usher, Annah N. Abrams. (2006) Psychopharmacology in Pediatric Critical Care. Child and Adolescent Psychiatric Clinics of North America 15:3, 611-655
     

334. 334

     Marcus C. Rosenhagen, Ulrike Schmidt, Frank Weber, Axel Steiger. (2006) Combination Therapy of Lamotrigine and Escitalopram May Cause Myoclonus. Journal of Clinical Psychopharmacology 26:3, 346-347
     

335. 335

     P. Ken Gillman. (2006) A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action. Biological Psychiatry 59:11, 1046-1051
     

336. 336

     K. R. Lawrence, M. Adra, P. K. Gillman. (2006) Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data. Clinical Infectious Diseases 42:11, 1578-1583
     

337. 337

     Donald E Craven. (2006) What is healthcare-associated pneumonia, and how should it be treated?. Current Opinion in Internal Medicine 5:3, 216-223
     

338. 338

     P. Ken Gillman. (2006) Extracting value from case reports: lessons from serotonin toxicity. Anaesthesia 61:5, 419-422
     

339. 339

     G. Alatrash, N. S. Majhail, J. C. Pile. (2006) Rhabdomyolysis After Ingestion of 'Foxy,' a Hallucinogenic Tryptamine Derivative. Mayo Clinic Proceedings 81:4, 550-551
     

340. 340

     Bertrand L. Jaber, Luis F. Lobon, Nicolaos E. Madias. (2006) The Serotonin Syndrome Complicating Co-prescription of Paroxetine and Clarithromycin. The American Journal of Medicine 119:4, e3
     

341. 341

     C. L. Sola, J. M. Bostwick, D. A. Hart, T. W. Lineberry. (2006) Anticipating Potential Linezolid-SSRI Interactions in the General Hospital Setting: An MAOI in Disguise. Mayo Clinic Proceedings 81:3, 330-334
     

342. 342

     P Ken Gillman. (2006) A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Human Psychopharmacology: Clinical and Experimental 21:2, 117-125
     

343. 343

     J. Soar, C. D. Deakin, J. P. Nolan, G. Abbas, A. Alfonzo, A. J. Handley, D. Lockey, G. D. Perkins, K. Thies, B. W. Böttiger, B. Dirks, V. Dörges, H. Domanovits, H. Gervais. (2006) Kreislaufstillstand unter besonderen Umständen. Notfall + Rettungsmedizin 9:1, 123-154
     

344. 344

     Moussa B H Youdim, Y S Bakhle. (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. British Journal of Pharmacology 147:S1, S287-S296
     

345. 345

     Aniceto Navarro, Christopher Perry, William V. Bobo. (2006) A case of serotonin syndrome precipitated by abuse of the anticough remedy dextromethorphan in a bipolar patient treated with fluoxetine and lithium. General Hospital Psychiatry 28:1, 78-80
     

346. 346

     R Kitson. (2006) A reply. Anaesthesia 61:1, 76-77
     

347. 347

     P. Ken Gillman. (2005) Understanding Toxidromes: Serotonin Toxicity. Journal of Clinical Psychopharmacology 25:6, 625-626
     

348. 348

     &NA;. (2005) A Cadillac Ride to the Emergency Department. Pediatric Emergency Care 21:12, 877-879
     

349. 349

     John C Morgan, Kapil D Sethi. (2005) Drug-induced tremors. The Lancet Neurology 4:12, 866-876
     

350. 350

     Jasmeet Soar, Charles D. Deakin, Jerry P. Nolan, Gamal Abbas, Annette Alfonzo, Anthony J. Handley, David Lockey, Gavin D. Perkins, Karl Thies. (2005) European Resuscitation Council Guidelines for Resuscitation 2005. Resuscitation 67, S135-S170
     

351. 351

     Nallini Gnanadesigan, Randall T. Espinoza, Rick Smith, Michelle Israel, David B. Reuben. (2005) Response to Letter From Dr. P.K. Gillman. Journal of the American Medical Directors Association 6:6, 423-425
     

352. 352

     Ahmed Elsayem, Eduardo Bruera. (2005) Methadone-Induced Respiratory Depression in a Patient with a History of Alcoholism. Journal of Palliative Medicine 8:5, 1062-1066
     

353. 353

     Geoffrey K Isbister, Nick A Buckley. (2005) The Pathophysiology of Serotonin Toxicity in Animals and Humans. Clinical Neuropharmacology 28:5, 205-214
     

354. 354

     Vincent Seutin. (2005) Dopaminergic neurones: much more than dopamine?. British Journal of Pharmacology 146:2, 167-169
     

355. 355

     Eric B Milbrandt, Derek C Angus. (2005) Potential mechanisms and markers of critical illness-associated cognitive dysfunction. Current Opinion in Critical Care 11:4, 355-359
     

356. 356

     Manju T. Beier. (2005) The Serotonin Syndrome Revisited. Journal of the American Medical Directors Association 6:4, 281
     

357. 357

     (2005) The Serotonin Syndrome. New England Journal of Medicine 352:23, 2454-2456
     Free Full Text

358. 358

     P. L. B. Bruijnzeel. (2005) Het serotoninesyndroom. Medisch-Farmaceutische Mededelingen 43:6, 194-195
     

359. 359

     W. D. Freeman, D. R. Chabolla. (2005) 36-Year-Old Woman With Loss of Consciousness, Fever, and Tachycardia. Mayo Clinic Proceedings 80:5, 667-670
     

Letters